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Over the past few decades, diabetes mellitus has become one of the largest epidemics the 
world has faced, making it an enormous challenge for modern healthcare systems. 
Between 2000 and 2020, overall prevalence of diabetes in adults snowballed from 151 
million to 463 million (Fig. 1). Today, this represents 9.3% of the world’s adult 
population aged 20-79 years. Without urgent multi-sectoral strategies and actions, 578 
million (10.2%) people are predicted to live with diabetes by 2030 and this number will 









Similarly to global trends the prevalence of diabetes has been increasing in Hungary (ca. 
7-9%) as well. According to the database analysis of the National Health Insurance Fund 
727 000 people are living with diabetes in Hungary (2). Diabetic patients have an 
increased risk of developing life-threatening health complications resulting in reduced 
quality of life, increased mortality and higher medical care costs. The global health 




Diabetes has a long history reaching back to antiquity. The term “diabetes” (Greek for 
“passing through” meaning “a large discharge of urine”) was first used in the 2nd century, 
while in the 17th century the term “mellitus” (Latin for “honey”) was added describing 
the extremely sweet taste of urine (4). Diabetes mellitus is a group of metabolic disorders 
associated with dysregulation of carbohydrate, lipid and protein metabolism. It is 
characterized by constant hyperglycemia resulting from a relative or absolute deficiency 
of insulin secretion or peripheral insulin resistance or both. Persistent hyperglycemia 
causes generalized vascular damage leading to several complications including 
cardiovascular diseases, neuropathy, retinopathy or kidney disease. 
 
Diabetes can be classified into various groups among which the following categories are 
the most frequent: 
1. Type 1 diabetes (T1DM; caused by autoimmune β-cell destruction, usually 
leading to absolute insulin deficiency). 
2. Type 2 diabetes (T2DM; caused by a progressive loss of β-cell insulin secretion 
frequently on the background of insulin resistance). 
3. Gestational diabetes mellitus (GDM) (diabetes diagnosed in the second or third 
trimester of pregnancy). 
4. Specific types of diabetes due to other causes e.g. monogenic diabetes syndromes 
(neonatal diabetes, maturity-onset diabetes of the young), diseases of the exocrine 
pancreas (cystic fibrosis, pancreatitis), drug- or chemical-induced diabetes and 





T1DM accounts for around 5-10% of diabetes in adults. It is characterized by autoimmune 
destruction of pancreatic β-cells leading to absolute insulin deficiency. The process is not 
fully understood, however many mechanisms can lead to the decline in β-cell function 
(e.g. genetic predisposition and abnormalities, epigenetic processes, auto-immunity, 
concurrent illnesses, inflammation and environmental factors) (6). The traditional 
paradigm saying that T1DM occurs only in children or adolescents has been disproven. 
Despite T1DM developing frequently in childhood, it can be manifested in adults as well 
(7). 
 
T2DM is the most common type of diabetes, accounting for more than 90% of all cases 
worldwide. T2DM is a complex chronic disorder primarily associated with insulin 
resistance in skeletal muscle, liver and adipose tissue and impaired insulin secretion. 
Environmental (e.g. obesity, unhealthy diet, physical inactivity) and genetic factors 
(T2DM clusters in families and is heritable) are important determinants of insulin 
resistance and β-cell dysfunction (8). T2DM mostly occurs in adults, however it has also 
become a concern in children and adolescents as a result of the increasing prevalence of 
obesity and metabolic syndrome in this population (9). 
 
GDM develops during pregnancy (generally detected in the second or third trimester) and 
resolves following delivery. GDM is currently the most common medical complication 
of pregnancy and its prevalence is increasing (10). In addition, the risk of developing 
T2DM in later life is substantially higher in women with GDM (11). Intrauterine exposure 
to diabetes is associated with increased lifetime risk of obesity and T2DM in the offspring 
as well (12). Detailed discussion of other specific types of diabetes (e.g. monogenic 
diabetes syndromes, diseases of the exocrine pancreas, endocrine disorders, drug- or 




The classic symptoms of hyperglycemia are polyuria, polydipsia, blurred vision, 
hyperphagia and weight loss. Children with T1DM typically present with the hallmark 




diabetic ketoacidosis (DKA) (13). The majority of patients with T2DM often remain 
undiagnosed for years, since hyperglycemia develops gradually and is not severe enough 
at earlier stages to notice the classic symptoms. Increased serum glucose levels are usually 
noticed during routine laboratory evaluation suggesting the onset of T2DM.  
 
Beside the classic symptoms of hyperglycemia, further blood glucose tests are needed for 
the diagnosis of diabetes. Fasting plasma glucose, two-hour plasma glucose during a 75 
g oral glucose tolerance test (OGTT), glycated hemoglobin (HbA1C) or random plasma 
glucose test in patients with classic symptoms of hyperglycemia or hyperglycemic crisis 
can be used for diagnostic testing. According to the current guidelines of the American 
Diabetes Association (ADA) and World Health Organization (WHO) diagnosis can be 
established if any of the following criteria is met: 
 Fasting plasma glucose ≥ 7.0 mmol/L 
 Two-hour plasma glucose ≥ 11.1 mmol/L during a 75 g OGTT 
 HbA1C ≥ 6.5%  
 Random plasma glucose ≥ 11.1 mmol/L 
 
“Prediabetes” is the term used for individuals whose serum glucose levels do not fulfil 
the criteria, but are higher than normal. Patients with increased fasting glucose (IFG; 6.1-
6.9 mmol/L) and/or impaired glucose tolerance (IGT; fasting plasma glucose < 7.0 
mmol/L and two-hour plasma glucose 7.8-11.1 mmol/L) and/or HbA1C 5.7-6.4% have 
prediabetes indicating a higher risk for the future development of diabetes and 




Patients with all forms of diabetes are at increased risk of developing serious acute and 
chronic complications. DKA and severe hypoglycemia are the major life-threatening 
acute complications of diabetic patients. Poor glycemic control, misdiagnosis, lack of 
access to insulin or low socioeconomic status result in acute complications leading to 





In general, the harmful effects of consistent hyperglycemia can be classified as chronic 
macrovascular complications (coronary artery disease, peripheral arterial disease) and 
microvascular complications (retinopathy, kidney disease, and neuropathy). 
Hyperglycemia exacerbates the development of atherosclerosis and heart failure, 
therefore CVD is the principal cause of death among diabetic patients (15). Diabetic 
retinopathy may be the most common microvascular complication of diabetes and is the 
leading cause of blindness in adults. Diabetic kidney disease (DKD) is the main topic of 
this thesis and will be discussed in detail in the next chapter. 
 




DKD is a major cause of chronic kidney disease (CKD) and end-stage renal disease 
(ESRD), accounting for approximately 50% of cases in the United States (16) and 30-
40% of cases in Hungary (17). It typically develops after 10 years of diabetes in the case 
of T1DM (ca. 30%), but may already be present at diagnosis of T2DM (ca. 40%) (18, 
19). The incidence of DKD has been increasing progressively parallels the dramatic 
worldwide rise of diabetes in the past decades. The annual healthcare cost of patients with 
DKD are 49% higher than diabetic patients with no kidney damage (20). 
 
1.2.2 Classification and diagnosis 
 
The clinical diagnosis of DKD is based on the presence of albuminuria and/or reduced 
estimated glomerular filtration rate GFR (eGFR) in the absence of signs or symptoms of 
other primary causes of kidney damage (e.g. rapidly decreasing eGFR, abrupt increase in 
albuminuria, nephrotic syndrome, refractory hypertension or eGFR decline within 2-3 
months of initiation of renin-angiotensin system inhibition). However, this paradigm may 
have changed over the last two decades. In particular, GFR loss has been observed prior 
to the development of albuminuria (21-23), reduced GFR without albuminuria has been 






Stage 1 known as glomerular hyperfiltration is characterized by kidney hypertrophy and 
normal albumin excretion. An absolute, supraphysiologic elevation in GFR is observed 
in this early clinical entity (28).  
 
Stage 2 develops silently over many years. Glomerular basement membrane (GBM) 
thickening without signs of clinical disease is a characteristic early change in diabetes. 
GBM thickening is a consequence of extracellular matrix (ECM) accumulation, with 
increased deposition of collagen types IV and VI, laminin and fibronectin (29, 30). A 
number of patients remain in stage 2 throughout their lives. 
 
Stage 3 is the forerunner of overt DKD. Diagnosis is supported by moderately increased 
urinary albumin excretion (UAE; 30-300 mg/24 hours) or albumin-to-creatinine ratio 
(ACR; 30-300 mg/g) confirmed by two independent measurements at least three months 
apart. A slow, gradual increase of albuminuria is a prominent feature of this very decisive 
phase of DKD when blood pressure is rising. Increased rate of UAE is higher in patients 
with elevated blood pressure. Expansion of cellular and matrix components in the 
Figure 2 Stages of diabetic kidney disease. The figure illustrates the 5 stages of diabetic kidney disease and the likely 
renal pathologic and functional alterations in each stage. Based on Mogensen et al., Diabetes. 1983;32 Suppl 2:64-78 
and Said and Nasr, Kidney International. 2016;90 1:24-26. 




mesangium and mild to moderate GBM thickening can be detected in stage 3 (31). GFR 
is normal or mildly decreased. 
 
Stage 4 is overt DKD. It is characterized by persistent, severe albuminuria (> 300 mg/24 
hours or ACR > 300 mg/g). Renal function declines (GFR < 60 mL/min/1.73 m2) when 
associated high blood pressure is left untreated. Segmental mesangiolysis can be observed 
with progression of diabetes and is associated with development of Kimmelstiel-Wilson 
nodules (32). These lesions consist of mesangial matrix accumulation with collagen 
fibrils, small lipid particles and cellular debris. 
 
Stage 5 is ESRD with uremia. It is characterized by decreased UAE due to glomerular 
loss and < 15 mL/min/1.73 m2 GFR. Dramatically reduced renal function leads to fluid 
retention, hypertension, anemia, disturbances of bone and mineral metabolism, 
dyslipidemia and protein energy malnutrition. Excessive accumulation of ECM proteins 
in the mesangial space and Kimmelstiel-Wilson lesions finally result in advanced 
glomerulosclerosis. Interstitial fibrosis and tubular atrophy follow glomerular changes 




DKD is a complex and heterogeneous disease with numerous overlapping metabolic and 
hemodynamic pathways. Hyperglycemia affects most renal cell types; however, some 
cells are more vulnerable to high glucose concentrations than others. Cells that are unable 
to regulate glucose uptake are the most sensitive to changes in the diabetic milieu (34). 
Glucose entry into proximal tubular cells is insulin independent; therefore, these cells are 
not capable of decreasing glucose transport adequately making them particularly 
susceptible to high glucose concentrations (35). Hyperglycemia not only affects tubular 
structures, but also enhances tubular glucose load, exposure and reabsorption. As the 
tubule grows the amount of reabsorbed glomerular filtrate increases, thus less reaches the 
macula densa causing GFR increment through the normal physiologic action of the 
tubuloglomerular feedback (TGF) system (36). Therefore, the proximal tubule may play 




Prolonged hyperglycemia results in production of advanced glycation end products 
(AGE), activation of the hexosamine and polyol pathway, increased vasoactive renin-
angiotensin-aldosterone system (RAAS) activity and hypoxia. All these glucose-induced 
general mechanisms change renal hemodynamics and promote renal inflammation and 
fibrosis (37). 
 
1.2.3.1 Renin-angiotensin-aldosterone system 
 
Systemic, circulating RAAS is involved in numerous physiological functions that 
regulate vasoconstriction, fluid volume regulation, cardiac output and vascular wall 
integrity. RAAS is a coordinated hormonal cascade that is initiated through renin 
synthesis in juxtaglomerular cells. Renin enzymatically cleaves liver-derived 
angiotensinogen into angiotensin I (Ang I). Ang I is further converted to the biologically 
active peptide angiotensin II (Ang II), a potent vasoconstrictor by pulmonary angiotensin-
converting enzyme (ACE). Further investigations proposed that other peptidases (e.g. 
chymase, cathepsins) could regulate Ang II production as well (38). ACE not only 
generates Ang II but also degrades the vasodilator bradykinin, thus its activity serves to 
increase systemic vascular tone (39). ACE2, an enzyme homologue of ACE was 
identified in the kidney and heart. Their substrate specificities differ; ACE2 hydrolyzes 
Ang II to form Ang 1-7 400-fold more efficiently than Ang I which generates Ang 1-9 
(40-42). These peptides have several opposing actions. Ang II mediates effects via 
complex intracellular signaling pathways binding to Ang II type 1 receptor (AT1R) and 
Ang II type 2 receptor (AT2R). Circulating Ang II regulates blood pressure and 
electrolyte balance via its actions on vascular tone, aldosterone secretion, renal sodium 
handling, water intake, sympathetic activity and vasopressin release using the AT1R. Ang 
II stimulation of the AT2R promots vasodilation and growth inhibition, which generally 
opposes Ang II actions mediated via the AT1R (43). 
 
Data suggest that regulation of renal RAAS is partly independent of systemic circulation. 
Kidneys express all of the RAAS components necessary for Ang II generation. Renal 
angiotensinogen is localized in the proximal tubule, where it can interact with renin. 




tubular cells (44). In diabetes, high glucose concentration stimulates both 
angiotensinogen and renin synthesis resulting in Ang II increment (45, 46). Notably, Ang 
II increases angiotensinogen mRNA expression and this feedback loop establishes a 
vicious cycle in the kidney. The high Ang II levels and overactivated RAAS lead to 
elevated blood pressure, mesangial cell contraction with decreased surface area for 
filtration, renal cell proliferation and hypertrophy, increased production of ECM, 
induction of growth factors and reactive oxygen species (47, 48). Further, Ang II is a 
major regulator of Ang II-dependent aldosterone release leading to renal fibrosis (49). 
Transforming growth factor-β (TGF-β) plays a crucial role in Ang II-dependent renal 
pathology contributing to epithelial-mesenchymal transition (EMT) (50). Along with 
TGF-β signaling, Ang II-induced fibrogenesis is also mediated through connective tissue 
growth factor (CTGF), plasminogen activator inhibitor-1 (PAI-1) and various 
inflammatory effectors leading to ECM production and renal fibrosis. 
 
1.2.3.2 Protein O-GlcNAcylation 
 
Protein O-GlcNAcylation is one of the most common post-translational modifications 
which was discovered in the early 1980’s (51). So far, more than four thousand proteins 
within the nucleus and cytoplasm have been shown to be modified by O-linked N-
acetylglucosamine (O‑GlcNAc) moiety. Unlike other glycosylation forms that consist of 
sequential chain elongation and complex branching, O-GlcNAcylation results in the 
addition of a single O-GlcNAc moiety (52). O‑GlcNAcylation is the product of nutrient 
flux through the hexosamine biosynthetic pathway (HBP) to generate uridine diphosphate 
GlcNAc (UDP-GlcNAc) substrate for O‑GlcNAcylation. Concentration of UDP-GlcNAc 
is directly influenced by glucose, amino acids, fatty acids and nucleotides, thus O-
GlcNAc serves as a nutrient sensor to modulate cellular processes (e.g. signaling, 
transcription, cytoskeletal functions) in response to nutrient status (53). Under normal 
physiological conditions, the HBP accounts for 2-5% of glucose utilization. In diabetes, 
an undesirable effect of hyperglycemia is increased metabolic flux through the HBP 
leading to several diabetic complications (54). Higher flux via the HBP results in 









O‑GlcNAcylation is controlled by a pair of intracellular enzymes. O‑GlcNAc transferase 
(OGT) catalyses the addition of a GlcNAc moiety from the donor substrate UDP-GlcNAc 
to the hydroxyl groups of target proteins at serine and/or threonine residues, while 
O‑GlcNAcase (OGA) is responsible for removing β-D-N-acetylglucosamine residues 
from previously modified proteins. OGT is highly conserved but has three known splice 
Figure 3 Protein O‑GlcNAcylation is regulated by nutrient flux via the hexosamine biosynthetic pathway. The 
majority of glucose is used for glycolysis and glycogen synthesis, while the hexosamine biosynthetic pathway (HBP) 
accounts for 2-5% of glucose utilization. Glutamine-fructose‑6‑phosphate amidotransferase 1 (GFAT1) is the rate-
limiting enzyme of the HBP, which converts fructose‑6‑phosphate (Fru‑6P) into glucosamine‑6‑phosphate (GlcN‑6P). 
Subsequent acetylation of GlcN‑6P and uridylation of GlcN‑1P yields the donor substrate for protein O‑GlcNAcylation, 
uridine diphosphate GlcNAc (UDP-GlcNAc). O‑GlcNAc transferase (OGT) and O‑GlcNAcase (OGA) catalyse the 
addition and removal of O‑GlcNAc, respectively. Free GlcNAc can be recycled via the GlcNAc salvage pathway 
converting GlcNAc into GlcNAc‑6P that can be utilized by the HBP. Modified image of Yang X, Qian K; Nat Rev Mol 




variants defined as nucleocytoplasmic (ncOGT; 110 kDa), mitochondrial (mOGT; 103 
kDa), and short OGT (sOGT; 78 kDa), all of which vary in abundance between tissues. 
The three isoforms differ only in the number of N-terminal tetratricopeptide repeat (TPR) 
motifs which affects their substrate recognition (59). Evolutionarily conserved OGA has 
two major splice variants: the long (OGA-L; 130 kDa) and short (OGA-S; 75 kDa) 
isoforms. OGA-L is localized in the cytosol and nucleus, whereas OGA-S resides 
primarily in lipid droplets (Fig. 3) (60). 
 
A growing body of evidence demonstrates the importance of O-GlcNAcylation in insulin 
resistance and glucose toxicity, which are the fundamental pathological processes of 
diabetes. Literary data indicate that glutamine-fructose‑6‑phosphate amidotransferase 1 
(GFAT1), the rate-limiting enzyme of the HBP is expressed in most tissues involved in 
the development of diabetic complications (61). Increased GFAT activity appears to be 
associated with insulin resistance, postprandial hyperglycemia and oxidative stress in 
T2DM (62). In diabetes, enhanced O-GlcNAcylation contributes to the development of 
complications in several ways. Insulin-responsive glucose uptake is affected by O-
GlcNAcylation in skeletal muscle and adipose tissue (63). Furthermore, O-
GlcNAcylation contributes to insulin resistance in adipocytes (64). In addition, 
deterioration of insulin secretion and pancreatic β-cell death is in part a consequence of 
diabetes-related increased protein O-GlcNAcylation (65, 66).  
 
O-GlcNAcylation has a major role in the regulation of renal fibrosis. O-GlcNAcylation 
plays an essential role in high glucose-induced upregulation of PAI-1 and TGF-β 
expression contributing to the development of renal fibrosis (67-69). Further, 
hyperglycemia-induced O‑GlcNAcylation mediates fibrosis in mesangial cells (70). A 
study suggests that increased O-GlcNAcylation contributing to the development of renal 
injury and inflammation (71). All these data clearly support that disruption of O‑GlcNAc 






1.2.3.3 Hypoxia  
 
Renal oxygenation is based on a balance between O2 supply and consumption. A complex 
interplay between renal blood flow, GFR, O2 consumption and arteriovenous O2 shunting 
maintain renal O2 tension at constant levels (72). The kidneys are less than 1% of total 
body weight but use 10% of total O2 consumption. O2 is mostly utilized to fuel Na⁺/K⁺-
ATPase in proximal tubular cells, which regulates sodium reabsorption and other 
transport processes (e.g. solutes, glucose, amino acids). The kidney carries out its 
complex transport functions in a relatively narrow range of O2 tension; therefore, it is 
highly vulnerable to hypoxic injury (73).  
 
Numerous studies have highlighted the pivotal contribution of hypoxia to DKD (74). As 
early as 1994, Körner et al. reported that O2 consumption of proximal tubules isolated 
from STZ-diabetic rats is greater than that of control animals (75). These findings have 
been confirmed by various models and methods throughout the years. Palm et al. used 
Clark-type microelectrodes to show that renal tissue O2 tension is decreased in diabetic 
rats (76). Blood oxygenation level-dependent (BOLD) MRI demonstrated that hypoxia is 
present in the outer medulla as well (77). Renal hypoxia is a consequence of increased 
blood flow resulting in elevated GFR. In turn, this increases sodium and glucose 
reabsorption via sodium-glucose cotransporters (SGLT), which leads to enhanced 
Na+/K+-ATPase activity resulting in elevated O2 consumption. Further, a diabetes-related 
rapid decline in peritubular capillary density causes inadequate oxygen delivery to tubular 
cells making them susceptible to hypoxic injury. Collectively, all these processes lead to 
decreased tissue O2 tension.  
 
Cells harbor many mechanisms with which they withstand hypoxic challenges; low O2 
tension leads to activation of various genes facilitating adaptation (e.g. erythropoiesis, 
angiogenesis, iron and glucose metabolism) and survival. Although several transcription 
factors are participated in the control of hypoxia, hypoxia-inducible factor (HIF) system 
is the master regulator of this cellular response (78). HIF is a heterodimeric basic helix-
loop-helix complex consisting of an α-subunit (HIF-1α, HIF-2α, HIF-3α) and a β-subunit 




(PHD) and targeted for proteosomal degradation by the von Hippel-Lindau-E3 ubiquitin 
ligase complex. On the other hand, PHD is inactive and HIF-α degradation is inhibited 
during hypoxia, thus HIF signaling is activated. HIF-α translocates from the cytoplasm to 
the nucleus, where it dimerizes with HIF-1β. The HIF complex then binds to hypoxia 
responsive elements in the promoter sequences of numerous genes involved in 
maintaining cellular and tissue O2 homeostasis e.g. erythropoietin (EPO), vascular 
endothelial growth factor (VEGF) and glucose transporter-1 (GLUT1) (Fig. 4). 
  
Figure 4 Oxygen regulates HIF-α protein expression. HIF is a heterodimeric transcription factor complex that is 
composed of an oxygen regulated HIF-1α subunit and a constitutively expressed HIF-1β subunit. HIF-1 activity 
depends on the degradation of HIF-1α subunit. HIF: hypoxia-inducible factor, FIH: Factor-inhibiting hypoxia-inducible 




Several studies support the tubular ‘chronic hypoxia hypothesis’ as a dominant 
pathogenic pathway in DKD, which not only promotes its progression but also initiates 
(79-81). Hypoxia triggers fibrotic response in tubulointerstitial cells and enhances 
myofibroblast differentiation. In response to low O2 tension collagen I production is 
increased, while matrix-metallopeptidase (MMP) 2 is decreased leading to ECM 
accumulation (82). Hypoxia also induces TGF-β expression, moreover they can act 
synergistically in the regulation of VEGF and EPO (83, 84). Activation of HIF plays an 
important role in tubulointerstitial fibrosis via direct transcriptional regulation of PAI-1, 
TGF-β and CTGF (85). Tubular hypoxia contributes to the development of tubular 
atrophy and interstitial fibrosis in a vicious circle promoting DKD progression. Targeting 
these processes can offer novel opportunities for therapeutic intervention. 
 
1.2.3 Treatment of diabetic kidney disease 
 
Optimization of glucose and blood pressure control to reduce the risk or to slow the 
progression of DKD are the primary standards of medical care. ADA recommends that 
targets for glycemic control should be considered with respect to age, comorbidities and 
life expectancy of patients. According to ADA and Kidney Disease Improving Global 
Outcomes (KDIGO) guidelines the target HbA1C is about 7.0%. For hypertension 
management, blood pressure levels of 140/90 mmHg are generally recommended, 
however, blood pressure targets at 130/80 mmHg may be considered for patients based 
on anticipated individual benefits and risks. For DKD patients, dietary protein intake 
should be approximately 0.8 g/bwkg/day and restriction of dietary sodium intake may be 
useful as well. Avoiding alcohol and tobacco is highly recommended since smoking has 
already been identified as an independent risk factor of DKD. 
 
ACE inhibitors or ARBs are the preferred first-line medication regimen for blood pressure 
treatment in diabetic patients with hypertension and moderately increased UAE (86-88). 
If UAE is moderately increased ACE inhibitor or ARB therapy has been demonstrated to 
reduce cardiovascular events (89). However, combination of ACE inhibitors and ARBs 
increase the risk of adverse events (hyperkalemia and/or acute kidney injury) and offers 




antagonists (also known as mineralocorticoid receptor antagonists) combined with ACE 
inhibitors or ARBs are an area of great interest. Aldosterone antagonists are effective for 
treatment of resistant hypertension, have been shown to reduce albuminuria in short-term 
studies of DKD and may have additional cardiovascular benefits. Contrarily, dual therapy 
may results in increased hyperkalemic episodes (92, 93). 
 
1.3 Role of the kidney in glucose metabolism 
 
Renal involvement in glucose metabolism was first described in the 1930s. The kidney 
bears a crucial role in the regulation of glucose homeostasis in three different ways: (I) 
glucose utilization for its energy needs; (II) glucose release through gluconeogenesis; (III) 
tubular glucose reabsorption from glomerular filtrate. Although each of these can be 
altered in diabetes, the focus of this thesis is summarizing the mechanism of glucose 
reabsorption targeted in the management of diabetes. 
 
1.3.1 Renal glucose reabsorption is mediated by SGLT2 and SGLT1 
 
The kidney of a normoglycemic person filters ~180 g glucose per day. Almost all filtered 
glucose (ca. 99%) is reabsorbed and urine is essentially glucose free. Experiments on 
isolated rabbit proximal convoluted tubules in the early 1980s proved the presence of two 
different glucose transporters along the apical surface (94). Wright et al. demonstrated 
the existence of two proximal tubular Na+/glucose cotransporters by molecular cloning: 
SGLT2 and SGLT1 as the primary mechanisms of glucose reabsorption in the kidney 
(95). Later, it was confirmed that low-affinity high-capacity SGLT2 protein is localized 
in the early proximal tubule (S1 and S2 segments), while high-affinity low-capacity 
SGLT1 is expressed in the late proximal tubule (S3 segment) in rodents using validated 
antibodies and knockout mice (96, 97). Recent studies showed the same expression 





Tubular glucose reabsorption requires a driving force through the apical to the basolateral 
membrane. Na+ and glucose are co-transported from the tubular lumen to the intracellular 
space through SGLTs by a Na+ dependent electrochemical gradient. Intracellular glucose 
is reabsorbed via GLUT1 or GLUT2, while sodium is reclaimed by Na+/K+-ATPase on 
the basolateral membrane, thus releasing them into the bloodstream. The majority of 
luminal glucose (ca. 97%) is reabsorbed in the early proximal tubule through SGLT2. 
The transport of Na+ and glucose occurs in a 1:1 ratio. SGLT1 reclaims the remaining 3% 
luminal glucose in the late proximal tubule with a Na+:glucose coupling ratio of 2:1 (Fig. 
5). All of the above was demonstrated by renal clearance and micropuncture studies in 
euglycemic Sglt1-/- and Sglt1/Sglt2 double knockout mice (99).  
 
 
Figure 5 Renal glucose reabsorption is mediated by SGLT2 and SGLT1. (A) SGLT2 reabsorbs ∼97% and SGLT1 
reabsorbs ∼3% of filtered glucose in the proximal tubules. (B) Diabetes increases the expression of SGLT2. This may 
be due to increased angiotensin II (Ang II) levels, hepatocyte nuclear factor HNF-1α and/or tubular growth. 
Hyperglycemia and increased SGLT2 expression enhance glucose and Na+ reabsorption in the proximal tubule. Glucose 
exits via basolateral GLUT2 to the blood stream. The relevance of luminal translocation of GLUT2 in diabetes remains 
to be determined. The elevation in filtered glucose and SGLT2 expression enhance the glucosuric effect of SGLT2 




Renal glucose filtration and the tubular glucose reabsorption are enhanced to around 600 
g per day in T1DM and T2DM. If GFR is normal, the renal transport maximum of glucose 
is reached when blood glucose levels exceed 11.1 mmol/L leading to a linear increase in 
glucosuria (100, 101). This process acts as a renal safety valve preventing extreme 
hyperglycemia. The elevated renal transport capacity of glucose is a consequence of 
tubular growth (102) or primary upregulation of SGLT2 or SGLT1 in diabetes (103, 104). 
Diabetes-induced enhanced glucose reabsorption contributes to prolonged 
hyperglycemia, therefore it can be thought to be maladaptive. The tubular reabsorption 
capacity of glucose is reducing to the residual capacity of SGLT1 (~80 g/day) in response 
to SGLT2 inhibition. That is to say, SGLT2 inhibition causes the renal safety valve to 
open at a lower threshold resulting in normoglycemic and moderately hyperglycemic 
range of glucose homeostasis (Fig. 6). 
 
Figure 6 Glucose reabsorption in the kidneys. The kidney of a normoglycemic person filters ~180 g glucose per day. 
Almost all filtered glucose (ca. 99%) is reabsorbed and urine is essentially glucose free. The majority of luminal glucose 
(ca. 97%) is reabsorbed in the early proximal tubule through Na+/glucose cotransporter 2 (SGLT2). Renal glucose 
filtration and the tubular glucose reabsorption are enhanced in diabetes. SGLT2i induce sustained glucosuria associated 




SGLTs belong to the SLC5 gene family including six isoforms of the SGLT gene. SGLT1 
and SGLT2 are the best characterized cotransporters. SGLT1 is expressed mainly in the 
brush border membrane of the intestines and the kidney mediating glucose and/or 
galactose absorption. SGLT2 is localized in the proximal tubules and facilitates glucose 
reabsorption from the glomerular filtrate. SGLT3 as a renal glucose sensor and/or 
transporter has only recently been discovered. SGLT4-6 have also been identified but 
their function and structure is unknown yet (105).  
 
Glucose-galactose malabsorption is an autosomal recessive disorder and is a consequence 
of a genetic mutation in SGLT1 leading to severe diarrhea (106). Individuals with 
mutations in SGLT2 gene are diagnosed as having familiar renal glucosuria. Patients with 
familiar renal glucosuria have reduced tubular glucose reabsorption resulting in persistent 
glucose excretion of 60-150 g/1.73 m2 per day without hyperglycemia. Most patients do 
not develop significant clinical complications over time, however the disorder can be 
associated with polyuria, polydipsia, polyphagia and recurrent urinary tract infections 
(107). These observations supported the potential role of SGLT2 inhibitors (SGLT2i) as 
safe glucose lowering drugs. SGLT2i act by inhibiting glucose reabsorption in renal 
proximal tubules, thereby lowering plasma glucose levels in an insulin-independent 
manner. 
 
1.4 Novel antidiabetic drugs: SGLT2 inhibitors 
 
The history of SGLT inhibitor development began with phlorizin, a natural flavonoid and 
dietary constituent contained in various fruit trees. It was first isolated from the bark of 
an apple tree in 1835 by French chemists (108). Phlorizin is a potent glucosuric agent and 
played a key role in uncovering the function of renal glucose reabsorption and the 
discovery of SGLTs. Phlorizin turned out to be a non-selective inhibitor of both SGLT2 
and SGLT1. Since blocking SGLT1 leads to glucose-galactose malabsorption associated 
with diarrhea, phlorizin was not considered a suitable drug candidate. Further, it has poor 
metabolic stability due to rapid hydrolysis by β-glucosidase resulting in low oral 
bioavailability, short plasma half lives and toxic effects of the aglycon phloretin. To 




modified in the late 1990s. The O-glucoside analog T-1095 showed promising glucose 
lowering effects in several diabetes models, however its development was discontinued 
in phase II (109). Several O-glucoside SGLT2 inhibitors were developed, but all “first 
generation” compounds were rejected due to the metabolic lability of the O-glucoside 
bond resulting in insufficient plasma half life. This problem was solved by C-glucoside-
based “second generation” SGLT2i providing greater resistance to β-glucosidase, hence 
greater oral bioavailability. This discovery has led to the development of longer-acting 
and more selective SGLT2i. 
 
Dapagliflozin (DAPA) was the frontrunner of C-glucoside-based SGLT2i development. 
The in vitro SGLT inhibitory potential (EC50) of DAPA is 1.1 nM for human SGLT2, 
equaling 1200-fold selectivity for SGLT2 over SGLT1 compared with phlorizin’s 10-fold 
selectivity. This proved that DAPA is a metabolically robust and selective SGLT2 
inhibitor (110). Forxiga™ (DAPA) was the first agent approved by the European 
Medicines Agency (EMA) for the treatment of T2DM in April 2012, followed by the 
Food and Drug Administration (FDA) in the United States shortly after. DAPA was 
followed by canagliflozin and empagliflozin; all three have been approved in the United 
States and in the European Union. Ipragliflozin, tofogliflozin and luseogliflozin have 
been approved in Japan. This new class of oral drugs is generally well tolerated and all of 
them induce sustained glucosuria associated with good blood glucose lowering effect in 
T2DM. Due to SGLT2i’s unique insulin-independent mode of action, their efficacy does 
not decrease with progressive β-cell dysfunction and/or insulin resistance. Further, 
SGLT2i can be prescribed as add-on therapy to other antidiabetic agents. 
 
Metabolic control in diabetes requires lifelong treatment, thus drug safety is of paramount 
importance. Human trial reports on the safety and efficacy of SGLT2i have not revealed 
major adverse side effects. Despite of this, genital and urinary tract and mycotic infections 
are the most common salutary effects of SGLT2i; however, these were generally mild to 
moderate in intensity. In addition, FDA issued a Drug Safety Communication warning in 
2015 that SGLT2i treatment may lead to euglycemic DKA. Cases have been reported in 
both T1DM and T2DM diabetic patients. Euglycemic DKA is a consequence of lower 




ketogenesis. Of note, the FDA identified potential triggering factors of DKA e.g. 
intercurrent illness, reduced food and fluid intake, reduced insulin doses and history of 
alcohol intake. Despite of this, the Empagliflozin Cardiovascular Outcome Event Trial in 
Type 2 Diabetes Mellitus Patients-Removal of Excess Glucose (EMPA-REG 
OUTCOME) study did not find any difference in rates of ketoacidosis in T2DM patients 
treated with empagliflozin vs. placebo. Nevertheless, further studies are needed to define 
the clinical relevance and the mechanisms involved. 
 
1.4.1 Pleiotropic effects of SGLT2 inhibitors 
 
The proof of cardiovascular safety for new glucose-lowering therapies has been required 
by FDA since 2008. Empagliflozin, canagliflozin, and dapagliflozin have been evaluated 
for cardiovascular safety in large-scale multicenter clinical trials: EMPA-REG 
OUTCOME, Canagliflozin Cardiovascular Assessment Study (CANVAS) and 
Dapagliflozin Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarction 
58 (DECLARE-TIMI 58), respectively (111-113). Each of these trials showed low 
incidence of heart failure and mitigated loss of kidney function in patients with T2DM 
and cardiovascular disease. These data indicate that renoprotection may be a class effect 
of SGLT2i. The objective of these trials was to investigate the cardiovascular safety of 
SGLT2i, hence subjects at high cardiovascular risk were primary enrolled and only 
relatively few patients with established CKD were included. Improved renal outcomes in 
these trials suggested that SGLT2i might also improve renal outcomes for patients with 
established DKD. The Canagliflozin and Renal Events in Diabetes with Established 
Nephropathy Clinical Evaluation (CREDENCE) trial recently proved that SGLT2i slow 
the progression of DKD. Patients with T2DM and albuminuric CKD (ratio of albumin 
[mg] to creatinine [g], >300 to 5000 and eGFR 30-90 mL/min/1.73 m2) who were already 
receiving RAAS blockers were enrolled in the CREDENCE study. The progression to 
ESRD, a doubling of the creatinine level or death from renal failure were 34% lower in 
the SGLT2i treatment group vs. placebo at a median follow-up of 2.6 years (114). Another 
ongoing clinical trial, A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes 
and Cardiovascular Mortality in Patients With Chronic Kidney Disease (DAPA-CKD) is 




with chronic kidney disease (eGFR 25-75 mL/min/1.73m2). Comparison studies suggest 
that SGLT2i are more renoprotective than other antidiabetics (e.g. GLP analogues) with 
similar glucose lowering effect (115). These results were substantiated by another study 
in which reduced albuminuria was independent of changes in HbA1c, blood pressure or 
body weight in DAPA-treated T2DM patients (116). Thus, renoprotection may arise not 
only beacuse of lower glucose levels, but due to other mechanisms of SGLT2i, such as 
inhibition of TGF, anti-inflammatory or anti-fibrotic effects. These renoprotective 
outcomes are encouraging and indicate that SGLT2i offer a promising therapeutic option 
in the future management of patients with T2DM. 
 
1.4.2 SGLT2 inhibitors for the treatment of type 1 diabetes 
 
DAPA is the first SGLT2i approved in the European Union as an adjunct to insulin in 
T1DM adults with a body mass index (BMI) of  ≥ 27 kg/m2, when insulin alone does not 
provide adequate glycemic control despite optimal insulin therapy. The therapeutic 
efficacy of DAPA as an adjunct to insulin in adult patients with insufficiently controlled 
T1DM was assessed in 24-week, phase III studies, Dapagliflozin Evaluation in Patients 
with Inadequately Controlled Type 1 Diabetes (DEPICT)-1 and in DEPICT-2. The results 
of DEPICT-1 showed a significant reduction in HbA1c, body weight, total insulin dose 
and glycemic variability with no increase in the risk of hypoglycemia or DKA (117). 
Improved HbA1c, mean glucose levels, glycemic variability and time in glycemic target 
range with no increase in hypoglycemia vs. placebo were demonstrated in DEPICT-2. 
Although there were several events of DKA in patients receiving DAPA (118). Overall, 
the DEPICT trials provide short-term evidence for using DAPA as adjunct therapy to 
adjustable insulin to improve glycemic control in T1DM patients. Therefore, the aim of 
my PhD work was to investigate the potential protective properties of DAPA as a 









The objective of our study was to identify new therapeutic options in the management of 
DKD. Based on the current literary data indicating that SGLT2i are renoprotective beyond 
their blood glucose lowering properties, the aim of our experiments was to investigate the 
potential antifibrotic effects of DAPA in DKD with special focus on protein O-
GlcNAcylation and tubular hypoxia. We also wanted to compare the renoprotective 




1. To determine the antifibrotic and renoprotective effects of various RAASi in 
monotherapy in experimental model of T1DM 
 
2. To investigate the safety and efficacy of DAPA and DAPA combined with ARB 
losartan in T1DM  
 
3. To analyze the protective effects of DAPA in DKD 
 
4. To evaluate the possible antifibrotic role of DAPA both in vivo and in vitro 
 
5. To determine the effects of DAPA and DAPA combined with losartan on protein O-










All experiments were conducted in accordance with guidelines of the Committee on the 




All chemicals and reagents were purchased from Sigma-Aldrich (St. Luis, MO, USA) and 
all standard plastic laboratory equipment was purchased from Sarstedt (Numbrecht, 
Germany) unless stated otherwise. 
 
3.1 Animals and experimental design 
 
Experiments were performed on eight-week old male Wistar rats (Rattus norvegicus) 
purchased from Toxi-Coop Ltd. (Budapest, Hungary). Rats were housed in plastic cages 
under a 12-hour light/dark cycle at constant temperature (24±2 °C) with ad libitum access 
to standard rodent chow and tap water. 
 
Diabetes was chemically induced with a single intraperitoneal injection of 65 mg/bwkg 
streptozotocin (STZ) dissolved in 0.1 M citrate buffer (pH 4.5). Blood glucose levels were 
measured with a Dcont Ideal device (77 Elektronika, Budapest, Hungary) three times 
from tail vein. Rats with a peripheral blood glucose value above 15 mmol/L 72 hours after 








After five weeks of diabetes rats were randomized into five groups (n=7-8/group) and 
were treated daily by oral gavage for 2 weeks as follows: 
1. isotonic saline as vehicle (D) 
2. enalapril dissolved in isotonic saline (D + ENA; 40 mg/bwkg/day) 
3. losartan dissolved in isotonic saline (D + LOS; 20 mg/bwkg/day) 
4. spironolactone dissolved in isotonic saline (D + SPI; 50 mg/bwkg/day) 
5. eplerenone dissolved in isotonic saline (D + EPL; 50 mg/bwkg/day). 
 
Doses were adopted from our previous studies in line with literary data where effective 
blockade of ACE, AT1R or aldosterone activity was achieved without changes in 
systemic blood pressure (119-121). Non-diabetic, age-matched controls (n=7-8/group) 
received equivalent volumes of citrate buffer without STZ once, and the same amount of 
saline by oral gavage daily at the same time as the diabetic animals throughout the 2-week 
treatment period (Fig. 7). 
 
  
Figure 7 Experimental design of Protocol I. After five weeks of diabetes rats were randomized into five groups (n=7-
8/group) and were treated daily by oral gavage for 2 weeks with isotonic saline as vehicle or D+ENA: D+enalapril, 





Rats were randomly divided into three groups immediately after the onset of diabetes 
(n=6 in D and n=7 in treatment groups) and were treated per os as follows: 
1. isotonic saline as vehicle (D) 
2. DAPA dissolved in isotonic saline (D + DAPA; 1 mg/bwkg/day for six weeks) 
3. DAPA + losartan dissolved in isotonic saline (D + DAPA + LOS; 1 mg/bwkg/day 
DAPA for six weeks + 20 mg/bwkg/day losartan in the last three weeks of the 
protocol) 
 
Age-matched controls (n=6) received the equivalent volume of citrate buffer without STZ 
once, and the same amount of saline by oral gavage daily at the same time as the diabetic 
animals during the 6-week study period. Rats were weighed daily; blood glucose levels 
were measured weekly. Blood pressure, serum and urinary parameters were determined 





Figure 8 Experimental design of Protocol II. Rats were randomly divided into three groups immediately after the 
onset of diabetes (n=6 in D and n=7 in treatment groups) and were treated per os as follows: isotonic saline as vehicle 
(diabetic) or dapagliflozin (D+DAPA) or dapagliflozin + losartan (D + DAPA + LOS; DAPA for six weeks + losartan 




In both protocols, rats were placed into metabolic cages to collect urine for a 24-hour 
period before euthanasia. At the end of the experiments rats were anesthetized by a 
mixture of 75 mg/bwkg ketamine (Richter Gedeon, Budapest, Hungary) and 10 mg/bwkg 
xylazine (Medicus Partner, Biatorbagy, Hungary) after which terminal blood was drawn 
from the abdominal aorta to sacrifice the animals. Blood, urine and kidney samples were 
collected and stored for further investigations. 
 
3.2 Measurement of arterial blood pressure 
 
Systolic and diastolic pressures were measured on tail vein using a CODA Standard 
monitor system (EMKA Technologies, Paris, France) which uses clinically validated 
proprietary volume pressure recording. Mean arterial pressure (MAP) was calculated.  
 
3.3 Metabolic and renal parameters 
 
Serum and urinary parameters were photometrically determined with commercially 
available kits on a Hitachi 912 photometric chemistry analyzer (Roche Hitachi, Basel, 
Switzerland). Creatinine clearance, albumin excretion and glucosuria were determined 
from 24-hour collected urine. Urinary kidney injury molecule-1 (KIM-1) and neutrophil 
gelatinase-associated lipocalin (NGAL) levels were measured using rat specific enzyme-
linked immunosorbent assays (ELISA) (R&D Systems, Minneapolis, MI, USA). 
 
3.4 Cell cultures and experimental design 
 
Human proximal tubular epithelial cell line (HK-2; LGC Standards, ATCC Cat#CRL-
2190, American Type Culture Collection, Manassas, VA, USA) was grown in DMEM 
(5.5 mM or 25 mM D-glucose) supplemented with 10% FBS, 1% L-glutamine, 1% 
antibiotic, antimycotic solution containing 10,000 IU/mL penicillin, 10 mg/mL 
streptomycin and 25 mg/mL Amphotericin B (Thermo Fisher Scientific, Waltham, MA, 
USA). Cells were incubated at 37 °C in a humidified atmosphere of 5% CO2 and 95% air. 




(1.2×105 cells/well) and there was a growth arrest period of 24 hours in serum-free 
medium before treatment in all experiments. Three sets of experiments were performed.  
 
Hyperglycemia model 
The effect of high glucose was tested on HK-2 proximal tubular cells cultured in DMEM 
containing 5.5 mM glucose and treated with high glucose (HG; final cc. 35 mM) or high 
mannitol (final cc. 35 mM) for 24 hours. HG cells were treated with 10 µM DAPA (HG 
+ DAPA; Santa Cruz Biotechnology Inc., Heidelberg, Germany) or 10 µM DAPA 
combined with 10 µM LOS (HG + DAPA + LOS) for 24 hours. Cells in 5.5 mM glucose 
conditions served as controls and mannitol treated cells were used for testing 
hyperosmolarity per se.  
 
Hypoxia model 
Hypoxia was induced in bold line stage top CO2/O2 incubator (Okolab, Ottaviano, Italy) 
by keeping the cells in 1% O2 for 2 hours. HK-2 cells cultured in medium containing 25 
mM glucose were treated as follows: 10 µM DAPA (H + DAPA) or 10 µM DAPA 
combined with 10 µM LOS (H + DAPA + LOS) for 24 hours before harvest. Cells were 
harvested at the end of hypoxia. Cells cultured under normoxic conditions served as 
controls. 
 
Cell viability and proliferation assay 
 
Prior to the experiments, the non-toxic dosage of DAPA and LOS was confirmed by 
methyl-thiazoletetrazolium assay (MTT) (Roche Diagnostics, Mannheim, Germany). 
Cell viability was determined by MTT assay according to the manufacturer’s instructions.  
 
Cell viability was also assessed by trypan blue exclusion. Cells were detached with 
trypsin-EDTA and re-suspended in medium diluted 1:1 with trypan blue solution. Live 





3.5 Conventional renal histology  
 
Periodic acid-Schiff staining 
Renal cortex was separated under light microscope and fixed in 4% buffered formalin, 
embedded in paraffin and 5 µm thick sections were cut. Images were taken with a Zeiss 
AxioImager A1 light microscope (Zeiss, Jena, Germany). To evaluate mesangial matrix 
expansion sections were stained with periodic acid-Schiff (PAS). Twenty fields of x400 
magnification containing glomeruli were randomly selected per animal, excluding 
incomplete glomeruli along the sample edge. The ratio of mesangial area (number of 
pixels containing purple mesangial matrix deposition) per glomerular tuft area (total 
number of pixels in the glomerulus) was measured in each glomerulus. 
 
Masson's trichrome staining 
To evaluate tubulointerstitial fibrosis sections were stained with Masson’s trichrome. Ten 
fields of x200 magnification were randomly selected from cortical and cortico-medullary 
regions respectively per animal. The ratio of Masson-stanied fibrotic area (pixels 
containing stained interstitial fibrotic tissue) per total area (total number of pixels in the 
area) was measured in each field. 
 
Picrosirius red staining 
To evaluate collagen accumulation sections were stained with Picrosirius red. Ten fields 
of x200 magnification were randomly selected from cortical and cortico-medullary 
regions per animal. The ratio of Picrosirius red-stanied interstitial area per total area was 
measured in each field area to obtain the percentage of collagen deposition. 
 
Areas were measured with Panoramic Viewer software version 1.15.2 (3DHISTECH, 
Budapest, Hungary). Analysis was performed in a double blinded fashion with computer-
assisted morphometry using Adobe Photoshop CS6 (Adobe Inc., San José, CA, USA) and 







All reagents for and fibronectin immunohistochemistry were obtained from 
Hisztopatologia (Pecs, Hungary) respectively. Slides were deparaffinized in xylene, 
rehydrated in graded ethanol series and washed in dH2O. Heat-induced epitope retrieval 
was performed by boiling the paraffin-embedded tissue sections in citrate buffer (pH=6). 
Slides were peroxidase blocked and nonspecific attachments were inhibited with protein 
solution. Sections were incubated against fibronectin (ab2413; Abcam, Cambridge, MA, 
USA) antibody followed by peroxidase labelled anti-rabbit antibody. Fibronectin was 
visualized with HISTOLS-Resistant AEC Chromogen/Substrate System counterstained 
with hematoxylin and eosin and mounted with permanent mounting medium. Evaluation 




HK-2 cells were cultured in tissue culture chambers and various treatments or hypoxia 
were applied. After repeated washing cells were fixed in 4% paraformaldehyde, washed 
again with phosphate buffered saline (PBS) and permeabilized with Triton X-100. After 
blocking with 5% bovine serum albumin (BSA) cells were incubated with the same O-
GlcNAc and HIF-1α antibodies used for western blotting for overnight at 4 °C. After 
repeated washing cells were incubated with specific secondary antibodies: Alexa Fluor 
488 goat anti-mouse (A-11001; Invitrogen™, Carlsbad, CA, USA) and Alexa Fluor 488 
chicken anti-rabbit (A-21441; Invitrogen™) respectively for 1 hour at room temperature. 
Samples were washed with PBS and nuclei were counterstained with Hoechst 33342 
(4082S; Cell Signaling Technology Inc., Danvers, MA, USA). Cells were mounted with 
ProLong Glass Antifade Mountant then a glass coverslip was added (P36982, 
Invitrogen™). Appropriate controls were performed, omitting the primary antibody to 
assure specificity and to avoid autofluorescence. Cells were imaged using an inverted 
microscope (Ti2; Nikon, Tokyo, Japan) equipped with a 20x objective (CFI Plan 
Apochromat Lambda, N.A. 0.75). For the semi-quantitative evaluation of fluorescence 





3.8 Measurement of biomarkers of ECM formation and degradation 
 
The biomarkers rPRO-C3 (measuring collagen type III formation), uC3M (measuring 
collagen type III degradation by MMP-9), and TUM (measuring tumstatin, a collagen 
type IV fragment degraded by MMP-9) were measured in rat urine samples using 
competitive ELISA developed by Nordic Bioscience (Herlev, Denmark). Biomarker 
levels were normalized to urinary creatinine levels measured using the QuantiChromTM 
Creatinine Assay kit (BioAssay Systems, USA). The assays were carried out at Nordic 
Bioscience laboratories following previously described protocols (123). Briefly, a 
streptavidin-coated 96-well ELISA plate were coated with biotinylated peptide for 30 
min. Plates were washed and incubated with standard peptide or sample together with 
HRP-conjugated monoclonal antibody and incubated for overnight at 4°C (uC3M, rPRO-
C3) or 1 hour at room temperature (TUM). Plates were washed and incubated with 
3,3ʹ,5,5-tetramethylbenzidine (4380H, Kem-En-Tec, Taastrup, Denmark) for 15 min at 
room temperature in the dark. To stop the reaction, 1% sulfuric acid solution was added, 
and plates were analysed with the ELISA reader at 450 nm with 650 nm as reference 
(VersaMax, Molecular Devices, CA, USA).  
 
3.9 Quantitative RT-PCR 
 
Total RNA was extracted using the Total RNA Mini Kit (Geneaid Biotech Ltd, New 
Taipei City, Taiwan). The quality and quantity of isolated RNA was measured on a 
NanoDrop ND-1000 spectrophotometer (Baylor College of Medicine, Houston, TX, 
USA). 500 ng RNA was reverse-transcribed using Maxima™ First Strand cDNA 
Synthesis Kit for RT-qPCR (Thermo Fisher Scientific, Waltham, MA, USA) to generate 
first-strand cDNA. Tgfb1, Ctgf, Pdgfb, Fn1, Havcr1, Lcn2, Rn18S, TGFB1, CTGF, 
PDGFB, HIF1A, GAPDH and RN18S mRNA expressions were determined in duplicates 
using LightCycler 480 SYBR Green I Master enzyme mix (Roche Diagnostics, 
Indianapolis, IN, USA) and specific primers listed in Table 1. Primer sequences were 
designed using Lasergene PrimerSelect software version 7.1.0 (DNASTAR, Madison, 
WI, USA) based on nucleotide sequences from the nucleotide database of National Center 




version 1.5.0.39 (Roche Diagnostics, Indianapolis, IN, USA). Target gene expressions 
were normalized against Rn18S or RN18S mRNA or GAPDH housekeeping genes. 
 
Table 1 Sequences of primer pairs for quantitative RT-PCR. 
 




Forward: 5' GCACCGGAGAGCCCTGGATACC 3' 
Reverse: 5' CCCGGGTTGTGTTGGTTGTAGAGG 3' 
222 
Ctgf NM_022266.2 
Forward: 5' TCCACCCGGGTTACCAATGACAATAC 3' 
Reverse: 5' CTTAGCCCGGTAGGTCTTCACACTGG 3' 
195 
Pdgfb NM_031524.1 
Forward: 5' TCGATCGCACCAATGCCAACTTCC 3' 
Reverse: 5' CACGGGCCGAGGGGTCACTACTGT 3' 
236 
Fn1 NM_019143.2 
Forward: 5' GGGCCGGGGCAGATGGAAATG 3' 
Reverse: 5' CCCAATGCCACGGCCCTAACAGTA 3' 
142 
Havcr1 NM_173149.2 
Forward: 5' CGCAGAGAAACCCGACTAAG 3' 
Reverse: 5' CAAAGCTCAGAGAGCCCATC 3' 
194 
Lcn2 NM_130741.1 
Forward: 5' CAAGTGGCCGACACTGACTA 3' 
Reverse: 5' GGTGGGAACAGAGAAAACGA 3' 
194 
Rn18s NR_046237.1 
Forward: 5' GCGGTCGGCGTCCCCCAACTTCTT 3' 
Reverse: 5' GCGCGTGCAGCCCCGGACATCTA 3' 
105 
RN18S NR_003286.4 
Forward: 5' GGCGGCGACGACCCATTC 3' 
Reverse: 5' TGGATGTGGTAGCCGTTTCTCAGG 3' 
136 
HIF1A NG_029606.1 
Forward: 5' CATAAAGTCTGCAACATGGAAGGT  3' 
Reverse: 5' ATTTGATGGGTGAGGAATGGGTT3' 
148 
EPO NM_000799.4 
Forward:   5' - GAGCCCAGAAGGAAGCCATC - 3' 
Reverse:    5' - GTCAGCAGTGATTGTTCGGA - 3' 
71 
VEGFA NM_001025366.3 
Forward:   5' - GCAAGACAAGAAAATCCCTGTG - 3' 
Reverse:    5' - TGAGAGATCTGGTTCCCGAA - 3' 
220 
TGFB1 NM_000660.7 
Forward: 5' CGAGGCGCCCGGGTTATGC 3' 
Reverse: 5' GCGTGCGGCAGCTGTACATTGACT 3' 
174 
CTGF NM_001901.3 
Forward: 5' CTCCACCCGGGTTACCAATGACAA 3' 
Reverse: 5' CAGCATCGGCCGTCGCTACATACT 3' 
228 
PDGFB NM_002608.4 
Forward: 5' GCGCCGGGAGATCTCGAACACCT 3' 
Reverse: 5' AGATGGGGCCGAGTTGGACCTGAA 3' 
163 
GAPDH NM_001289745.3 
Forward: 5' AGCAATGCCTCCTGCACCACCAA 3' 








3.10 Western blot 
 
All reagents and equipment for Western blot were obtained from Bio-Rad Laboratories 
Inc. (Hercules, CA, USA) unless stated otherwise. Total protein was extracted from 
kidney cortex and HK-2 cells. Samples were homogenized in lysis buffer (1 M Tris, 0.5 
M EGTA, 1% Triton X-100, 0.25 M NaF, 0.5 M phenylmethylsulfonyl fluoride, 0.5 M 
sodium orthovanadate, 5 mg mL−1 leupeptin, and 1.7 mg mL−1 aprotinin, pH 7.4) by 
Fastprep RP120 homogenisator (Thermo Fisher Scientific). Lysates were centrifuged at 
13 000 rpm at 4°C for 10 min. Protein concentration of the supernatants was measured in 
96-well microplates with a DC™ Protein Assay kit at 650 nm by a SPECTROstar Nano 
microplate reader (BMG Labtech, Ortenberg, Germany). Protein samples were mixed 
with 4x Laemmli sample buffer (1:3) and heated at 95 °C for 5 minutes or 37 °C for 30 
minutes.  
 
Samples were electrophoretically resolved on polyacrylamide gradient gels (4-20%) and 
transferred to nitrocellulose membranes with fast and high-efficiency semi-dry Trans-
Blot Turbo™ Transfer System. The protein transfer was verified by 1% Ponceau S 
staining. After blocking, membranes were immunoblotted with specific primary 
antibodies. After repeated washing, the blots were incubated with the appropriate 
horseradish peroxidase (HRP)-conjugated secondary antibodies. LuminataTM Forte 
Western HRP Substrate (Millipore Corporation, Billerica, MA, USA) was used for 
chemiluminescent detection of blots. Details of antibodies are listed in Table 2 and Table 
3.  
 
Densitometric analysis of bands was performed by Quantity One Analysis software (Bio-
Rad Laboratories Inc.). After background subtraction, integrated optical densities of 
bands of interest were factored for Ponceau S staining to correct for variations in total 
protein loading. Each blot was normalized to an internal control so that bands on separate 





Table 2 List of primary antibodies used for Western blots. 
 
 




Target protein Manufacturer 
Catalog 
number 
Source Dilution buffer Dilution 
α-SMA 
Sigma Aldrich 




1% wt/vol non-fat 
milk, 1xTBS 0.4% 
wt/vol Tween 20 
1:500 
CTGF 





5% wt/vol non-fat 
milk, 1xTBS 0.1% 
wt/vol Tween 20 
1:500 
EPO 





5% wt/vol non-fat 
milk, 1xTBS 0.1% 








5% wt/vol BSA, 









5% wt/vol non-fat 
milk, 1xTBS 0.1% 








1% wt/vol BSA, 









1% wt/vol non-fat 
milk, 1xTBS 0.4% 
wt/vol Tween 20 
1:1000 
PDGF 





5% wt/vol non-fat 
milk, 1xTBS 0.1% 








5% wt/vol BSA, 1x 
TBS 0.1% wt/vol 
Tween 20 
1:1000 
Target protein Manufacturer 
Catalog 
number 
Source Dilution buffer Dilution 
Goat IgG 




1x TBS 0.05% 
wt/vol Tween 20 
1:3000 Mouse IgG 
Cell Signaling Technology Inc. 
Danvers, MA, USA 
7076 goat 
Rabbit IgG 
Cell Signaling Technology Inc. 





3.11 Statistical analysis 
 
Data are expressed as means±standard deviations (SD) or means±95% confidence 
intervals. Statistical analysis was performed using Prism software (version 7.0; GraphPad 
Software Inc., San Diego, CA, USA). Multiple comparisons and interactions were 
evaluated by one-way ANOVA followed by Holm-Sidak post hoc test. For non-
parametrical data, the Kruskal-Wallis ANOVA on ranks followed by with Dunn 






4.1 Effect of RAASi on metabolic parameters and renal function 
 
4.1.1 MAP remained unaltered in control, diabetic and RAASi-treated groups 
 
Our aim was to investigate the effect of RAAS blockade regardless of their 
antihypertensive properties. Doses were adopted from our previous studies in line with 
literary data. The protocol was successfully applied, since MAP remained unchanged in 
all groups confirming that the examined effects of RAASi are independent of their 
antihypertensive properties (Table 4). 
 
Table 4 Mean arterial pressure of control, diabetic and RAASi treated diabetic rats. Mean arterial pressure (MAP) 
values of control, diabetic (D) and RAASi-treated (D+ENA: D+enalapril, D+LOS: D+losartan, D+SPI: 
D+spironolactone, D+EPL: D+eplerenon) diabetic rats. Values indicate means±SDs and data were analyzed by oneway 






 Control Diabetic (D) D + ENA D + LOS D + SPI D + EPL 




4.1.2 RAASi are not affect metabolic parameters 
 
Metabolic parameters were evaluated after seven weeks of diabetes. Rats had significant 
weight loss, elevated blood glucose, fructosamine and lipid levels confirming the 
development of T1DM. RAASi did not alter any of these parameters. Enalapril and 
aldosterone antagonists improved cholesterol levels. Liver enzymes remained unaltered 
in all groups (Table 5). 
 
 
Table 5 Metabolic parameters of control, diabetic and RAASi treated diabetic rats. Values indicate means±SDs 
and data were analyzed by one-way ANOVA with Holm-Sidak multiple comparisons test (n=7-8 rats/groups). *p<0.05 
vs. Control, **p<0.01 vs. Control, §p<0.05 vs. Diabetic. GOT: serum glutamate-oxaloacetate transaminase. GPT: serum 





Metabolic Parameters Control Diabetic (D) D + ENA D + LOS D + SPI D + EPL 
Body weight (g) 418±23.4 276±28.9* 291±13.3* 258±24.8* 245±35.1* 288±20.9* 
Glucose (mmol/L) 12.7±1.15 47.3±7.80* 35.3±3.23* 43.8±4.79*  42.6±2.55* 34.8±3.57 
Fructosamine (μmol/L) 153±8.28 243±16.3** 250±5.09** 256±17.6** 239±11.5** 239±16.5** 
Cholesterol (mmol/L) 1.90±0.05 2.28±0.06* 1.82±0.10§ 2.06±0.08 1.72±0.11§ 1.82±0.14§ 
Triglycerides (mmol/L) 0.57±0.07 1.90±0.50
*
 0.99±0.43 1.31±0.37 1.13±0.12 0.88±0.09 
GOT (U/L) 168±8.20 221±27.0 186±21.6 158±31.6 160±14.7 156±12.2 




4.1.3 RAASi and renal function 
 
Development of DKD was confirmed by the decline of renal function. Creatinine 
clearance decreased, while serum creatinine, blood urea nitrogen (BUN) and UAE 
elevated in diabetic rats. ENA, SPI and EPL improved creatinine clearance. BUN and 
albumin excretion were significantly reduced by all treatments (Fig. 9). 
 
  
Figure 9 Renal function is improved by RAASi. (A) Creatinine clearance, (B) serum creatinine, (C) blood urea 
nitrogen (BUN) and (D) albumin excretion of control, diabetic (D) and RAASi treated (D+ENA: D+enalapril, D+LOS: 
D+losartan, D+SPI: D+spironolactone, D+EPL: D+eplerenon) diabetic rats. Values are presented as means±95% 
confidence intervals and data were analyzed by one-way ANOVA with Holm-Sidak multiple comparisons test or by 
Kruskal-Wallis test with Dunn correction (n=7-8 rats/group). *p<0.05 vs. Control, **p<0.01 vs. Control, §p<0.05 vs. 




4.1.4 Tubulointerstitial fibrosis and RAASi 
 
Renal interstitial fibrosis is a common pathological feature of progressive kidney 
diseases. Tubulointerstitial fibrosis was assessed on Masson’s trichrome-stained sections. 
The quantity of fibrotic connective tissue increased in diabetic rats. All of the RAASi 
decreased tubulointerstitial fibrosis (Fig. 10). 
 
  
Figure 10 RAASi reduce tubulointerstitial fibrosis. Representative Massonʹs trichrome-stained kidney sections of 
control, diabetic (D) and RAASi treated (D+ENA: D+enalapril, D+LOS: D+losartan, D+SPI: D+spironolactone, 
D+EPL: D+eplerenon) diabetic rats. Original magnification, x200. Scale bar, 100 µm. Quantitative evaluation of renal 
tubulointerstitial fibrosis by Masson-positive and glomerulus-free vs. total areas in the kidney cortex. Values are 
presented as means±95% confidence intervals and data were analyzed by one-way ANOVA with Holm-Sidak multiple 





4.2 DAPA prevents metabolic decline in diabetic rats 
 
As expected, DAPA markedly improved all the metabolic parameters that was elevated 
due to diabetes. Blood glucose levels were decreased in the first week, reaching a decline 
of 41% by the second week. By the end of the experiment, blood glucose levels were 47% 
lower in DAPA vs. diabetic group, which is in line with literary data. In parallel, urinary 
glucose excretion was enhanced in DAPA-treated groups. Hemoglobin levels were lower 
in diabetic rats but were restored by DAPA to control levels (Table 6). Our results confirm 
the efficacy of DAPA in T1DM experimental rat model. Combination therapy with LOS 
did not result in a synergistic effect. 
 
 
Table 6 Six weeks of DAPA treatment ameliorates T1DM-induced metabolic changes. Metabolic parameters of 
control, diabetic (D), dapagliflozin (D+DAPA) or DAPA+losartan (D+DAPA+LOS) treated diabetic rats at the end of 
the 6 week experimental period. Values indicate means±SDs and data were analyzed by one-way ANOVA with Holm-
Sidak multiple comparisons test (n=6 in control and diabetic and n=7 in treatment groups). *p<0.05 vs. Control, 
**p<0.01 vs. Control, §p<0.05 vs. Diabetic, §§p<0.01 vs. Diabetic. UN: undetermined, MAP: mean arterial pressure, 
LDL-C: low-density lipoprotein cholesterol, GOT: serum glutamate-oxaloacetate transaminase, GPT: serum 
glutamate-pyruvate transaminase 
 
Metabolic Parameters Control Diabetic (D) D + DAPA D + DAPA + LOS 
Body weight (g) 434±37.9 256±26.7** 333±39.2**§§ 312±37.8**§§ 
Non-fasting blood glucose (mmol/L) 6.52±0.57 33.0±1.12** 17.7±5.63**§§ 18.1±6.16**§§ 
Fructosamine (μmol/L) 142±4.12 274±13.6** 206±34.2**§§ 217±27.8**§§ 
Cholesterol (mmol/L) 1.98±0.14 2.69±0.41** 1.96±0.36§§ 2.26±0.34§ 
Triglycerides (mmol/L) 1.39±0.58 2.84±1.26** 1.08±0.58§§ 0.91±0.20§§ 
LDL-C (mmol/L) 0.44±0.15 0.84±0.12** 0.51±0.14§§ 0.77±0.13** 
GOT (U/L) 127±17.5 347±170** 191±25.4§ 214±88.6§ 
GPT (U/L) 42.8±7.54 166±82.2** 84.6±16.3§§ 65.2±10.8§§ 
Hemoglobin (g/L) 155±16.0 88.3±9.50** 149±9.45§§ 153±8.08§§ 




4.3 Diabetes-induced SGLT2 and GLUT2 increment are mitigated by DAPA  
 
Protein levels of SGLT2 and GLUT2 were upregulated in diabetic kidneys. This was not 
unexpected in light of multiple studies showing increased renal SGLT2 expression in 
various diabetic rodent models. DAPA treatment minimized protein levels of both 





4.4 DAPA slows the loss of renal function 
 
4.4.1 Renal retention parameters are improved by DAPA 
 
First, we investigated classic renal retention parameters. Development of DKD was 
confirmed by the decline of renal function after six weeks of diabetes. Creatinine 
clearance decreased, while serum creatinine, BUN and albumin excretion elevated in 
diabetic rats. DAPA markedly improved creatinine clearance, serum creatinine, BUN and 
albumin excretion (Fig. 12A-D). 
Figure 11 Diabetes-induced SGLT2 and GLUT2 increment are mitigated by DAPA. (A) Sodium-glucose 
cotransporter 2 and (B) glucose transporter 2 protein levels of control, diabetic (D), dapagliflozin (D+DAPA) and 
DAPA+losartan (D+DAPA+LOS) treated diabetic rats. Bars indicate means±SDs and data were analyzed by one-way 
ANOVA with Holm-Sidak multiple comparisons test or by Kruskal-Wallis test with Dunn correction (n=6 in control 








4.4.2 DAPA minimizes the early and sensitive biomarkers of tubular damage 
 
Recently, the interest of clinicians has focused on KIM-1 and NGAL (also known as 
lipocalin-2) as very early and highly sensitive biomarkers of renal tubular damage (124, 
125). Urinary excretion of KIM-1 and NGAL were elevated in the diabetic group vs. 
controls, while DAPA decreased their levels by more than 50% indicating milder tubular 
damage (Fig. 13A-B). In parallel, Havcr1 (KIM-1) and Lcn2 (NGAL) mRNA expressions 
were increased in the diabetic kidney as well (Fig. 13C-D). Furthermore, creatinine 
clearance correlated with urinary KIM-1 (R2=0.202. p=0.0252) and urinary NGAL 
(R2=0.546. p=0.0001), respectively (Fig. 13E-F). 
Figure 12 DAPA treatment slows the decline of renal function. (A) Creatinine clearance, (B) serum creatinine, (C) 
blood urea nitrogen (BUN) and (D) albumin excretion of control, diabetic (D), dapagliflozin (D+DAPA) and 
DAPA+losartan (D+DAPA+LOS) treated diabetic rats. Bars indicate means±SDs and data were analyzed by one-way 
ANOVA with Holm-Sidak multiple comparisons test (n=6 in control and diabetic and n=7 in treatment groups). 





Figure 13 Early and sensitive biomarkers of tubular damage is decreased by DAPA. (A) Urinary levels of kidney 
injury molecule-1 (KIM-1), (B) urinary levels of neutrophil gelatinase-associated lipocalin (NGAL), (C) renal Havcr1 
mRNA expression and (D) renal Lcn2 mRNA expression of control, diabetic (D), dapagliflozin (D+DAPA) and 
DAPA+losartan (D+DAPA+LOS) treated diabetic rats. (E,F) Scatter plot illustrating the correlation between creatinine 
clearance and KIM-1 or NGAL, resp. Bars indicate means±SDs and data were analyzed by one-way ANOVA with 
Holm-Sidak multiple comparisons test (n=6 in control and diabetic and n=7 in treatment groups). *p<0.05 vs. Control, 




4.4.3 DAPA ameliorates mesangial matrix expansion in the diabetic kidney 
 
Kidney sections were stained with PAS and mesangial fractional volume values (Vv) 
were defined by the ratio of mesangial area/glomerular tuft area. Histological changes 
were consistent with functional deterioration. Evaluation of PAS-stained sections 
revealed massive hypertrophy, mesangial matrix expansion and basal membrane 
thickening in the glomeruli of diabetic rat kidneys. DAPA minimized mesangial matrix 
expansion and ameliorated structural damage as reflected by smaller PAS positive 
glomerular areas (Fig. 14). 
 
 
Additional LOS treatment did not result in a synergistic effect in any of the investigated 
parameters. 
Figure 14 Mesangial matrix expansion was ameliorated in the diabetic kidney by DAPA. PAS-stained kidney 
sections of control, diabetic (D), dapagliflozin (D+DAPA) and DAPA+losartan (D+DAPA+LOS) treated diabetic rats. 
Mesangial area was determined by assessment of PAS-positive and nucleus-free areas in the mesangium. Original 
magnification, x400. Scale bar, 50 µm. Mesangial fractional volume values (Vv) were defined by the ratio of PAS-
stained mesangial area/glomerular tuft area.  Bars indicate means±SDs and data were analyzed by one-way ANOVA 
with Holm-Sidak multiple comparisons test (n=6 in control and diabetic and n=7 in treatment groups). *p<0.05 vs. 




4.5 Renal fibrogenesis is alleviated by DAPA 
 
4.5.1 Novel urinary fibrosis markers were diminished by DAPA 
 
Our collaborator partner, Nordic Bioscience develops novel urinary biomarkers of ECM 
remodeling, which are promising in early diagnosis and prognosis of renal fibrosis and 
might replace the invasive renal biopsy. In our experiment, collagen III formation (rPRO-
C3), MMP-9-mediated degradation of type III collagen (uC3M) and type IV collagen 
(TUM) were elevated in diabetic rats. DAPA treatment decreased rPRO-C3 and TUM 





Figure 15 Novel urinary biomarkers of ECM remodeling are decreased in the DAPA-treated diabetic rats. (A-
C) Urinary levels of N-terminal pro-peptide of type III collagen (rPRO-C3), collagen type III degradation fragment 
(uC3M) and collagen type IV degradation fragment tumstatin (TUM) of control, diabetic (D), dapagliflozin (D+DAPA) 
and DAPA+losartan (D+DAPA+LOS) treated diabetic rats. Bars indicate means±SDs and data were analyzed by one-
way ANOVA with Holm-Sidak multiple comparisons test (n=6 in control and diabetic and n=7 in treatment groups). 




4.5.2 DAPA mitigates profibrotic growth factor levels 
 
Profibrotic growth factors have a major role in the development of fibrosis in various 
organs including the kidneys. Here we investigated the renal mRNA expressions of Tgfb1, 
Pdgfb and Ctgf, which were upregulated in diabetic rats. DAPA decreased Pdgfb and Ctgf 






Figure 16 Profibrotic growth factor mRNA expressions were diminished by DAPA. (A) Transforming growth 
factor beta 1 (Tgfb1), (B) platelet derived growth factor subunit B (Pdgfb) and (C) connective tissue growth factor 
(Ctgf) of control, diabetic (D), dapagliflozin (D+DAPA) and DAPA+losartan (D+DAPA+LOS) treated diabetic rats. 
mRNA expressions were normalized to housekeeping Rn18S mRNA expression. Bars indicate means±SDs and data 
were analyzed by one-way ANOVA with Holm-Sidak multiple comparisons test (n=6 in control and diabetic and n=7 




4.5.3 Myofibroblast activation and tubulointerstitial fibrosis was decreased by 
DAPA 
 
The activated myofibroblast is the primary matrix secreting cell type. Alpha-smooth 
muscle actin (α-SMA), the best marker of the myofibroblast was investigated. Diabetes-
induced α-SMA increment was minimized by DAPA (Fig. 17A). The extent of diabetes-
induced tubulointerstitial fibrosis was evaluated on Masson’s trichrome-stained sections. 
Extensive tubulointerstitial fibrosis and dilated tubules were observed in diabetic kidneys. 
DAPA reduced the amount of renal fibrotic tissue (Fig. 17B-C).  
 
 
The combination with LOS had no synergistic effect in any of the investigated 
parameters.  
Figure 17 DAPA reduces tubulointerstitial fibrosis. (A) Alpha-smooth muscle actin (α-SMA) protein levels. Proteins 
were normalized to total protein Ponceau S staining as loading control. (B) Representative Massonʹs trichrome-stained 
kidney sections of control, diabetic (D), dapagliflozin (D+DAPA) and DAPA+losartan (D+DAPA+LOS) treated 
diabetic rats. Original magnification, x200. Scale bar, 200 µm. (C) Quantitative evaluation of renal tubulointerstitial 
fibrosis by Masson-positive and glomerulus-free vs. total areas in the kidney cortex. Bars indicate means±SDs and data 
were analyzed by one-way ANOVA with Holm-Sidak multiple comparisons test (n=6 in control and diabetic and n=7 




4.5.4 Correlation between tubulointerstitial fibrosis and urinary markers of ECM 
remodeling 
 
Correlation analysis was performed to strengthen the relevance of novel urinary markers 
of ECM remodeling in early diagnosis and prognosis of renal fibrosis. Positive correlation 
was found between tubulointerstitial fibrosis (evaluated on Masson’s trichrome-stained 
sections) and rPRO-C3 (R2=0.4459, p=0.0003), uC3M (R2=0.1922, p=0.0364) and TUM 
(R2=0.2285, p=0.0182), respectively (Fig. 18A-C). Our experimental results support the 







Figure 18 Tubulointerstitial fibrosis correlates with urinary markers of ECM remodeling. Scatter plots 
illustrating the correlation between Masson’s trichrome evaluation and N-terminal pro-peptide of type III collagen 





4.5.5 DAPA prevents renal collagen accumulation 
 
Collagens are the most common matrix components in renal fibrosis. Picrosirius Red 
staining was performed to assess accumulation of collagen components. Weak collagen 
staining was detected in glomeruli and around blood vessels in control kidneys. Extensive 
fibrotic tissue accumulation was observed in diabetic kidneys as shown by collagen 
deposition in the interstitium. Diabetes-induced collagen deposition was lower in the 
DAPA group compared to the diabetic group, while DAPA+LOS treatment had no 
additional effect (Fig. 19).  
Figure 19 Diabetes-induced collagen deposition are ameliorated by DAPA. Representative Sirius red-stained 
kidney sections of control, diabetic (D), dapagliflozin (D+DAPA) and DAPA+losartan (D+DAPA+LOS) treated 
diabetic rats. The ratio of Picrosirius red-stanied interstitial area per total area was measured to obtain the percentage 
of collagen deposition. Original magnification, x200. Scale bar, 100 µm. Bars indicate means±SDs and data were 
analyzed by one-way ANOVA with Holm-Sidak multiple comparisons test (n=6 in control and diabetic and n=7 in 




4.5.6 Diabetes-induced fibronectin accumulation is ameliorated by DAPA 
 
In renal fibrosis, deposition of the adhesive glycoprotein, fibronectin precedes the 
production of fibrillar collagens. Considerable fibronectin-positive staining was detected 
in the glomeruli and to a lesser extent in the tubulointerstitium of diabetic kidneys which 
was attenuated by both treatments (Fig. 3B,D). In parallel with histology, renal 
fibronectin mRNA expression increased in diabetes vs. controls and was decreased by 




DAPA+LOS combination has no additional effect on the decrement of fibronectin 
accumulation.  
Figure 20 DAPA reduces fibronectin deposition and mRNA expression. Representative fibronectin stained kidney 
sections of control, diabetic (D), dapagliflozin (D+DAPA) and DAPA+losartan (D+DAPA+LOS) treated diabetic rats. 
The ratio of mesangial area per glomerular tuft area was measured to obtain the percentage area of fibronectin 
accumulation. Original magnification, x400. Scale bar, 50 µm. Renal mRNA expression of fibronectin 1 (Fn1) was 
normalized to Rn18S mRNA expression. Bars indicate means±SDs and data were analyzed by one-way ANOVA with 
Holm-Sidak multiple comparisons test (n=6 in control and diabetic and n=7 in treatment groups). **p<0.01 vs. Control, 




4.6 Hyperglycemia-induced O-GlcNAcylation is prevented by DAPA in HK-2 cells 
 
Since SGLT2i act on proximal tubular cells, the direct effects of DAPA on O-
GlcNAcylation were investigated in HK-2 proximal tubular cells cultured in 
hyperglycemic conditions. Both Western-blot and immunocytochemistry measurements 
revealed that protein O-GlcNAcylation is induced after 24 hours of high glucose (HG) 
treatment. DAPA prevented HG-induced protein O-GlcNAcylation. The changes were 
not detected in mannitol-treated cells confirming that the observed phenomenon is a 
consequence of hyperglycemia and not hyperosmolarity (Fig. 21A-C). 
 
  
Figure 21 DAPA reduces hyperglycemia-induced protein O-GlcNAcylation in human proximal tubular cells 
(HK-2). Proximal tubular cells were incubated with normal glucose (5.5 mM), high mannitol (35 mM) or high glucose 
(35 mM) for 24 hours. (A) Total protein levels of O-GlcNAcylation and of control, mannitol, high glucose (HG), 
dapagliflozin (HG+DAPA) and DAPA+losartan (HG+DAPA+LOS) treated high glucose HK-2 cells. Proteins were 
normalized to total protein Ponceau S staining as loading control. (B) O-GlcNAc integrated density. (C) Representative 
immunocytochemistry staining and integrated density of O-GlcNAc (green O-GlcNAc; blue nucleus; 20x objective; 
scale bar, 50 μm). Bars indicate means±SDs and data were analyzed by one-way ANOVA with Holm-Sidak multiple 
comparisons test or Kruskal-Wallis with Dunn comparison test (n=5-6/group and n=10 visual fields/group). *p<0.05 




In parallel, levels of ncOGT and sOGT, the enzymes responsible for adding O-GlcNAc 
moiety were higher after 24 hours of HG treatment (Fig. 22A-B). DAPA prevented HG-
induced ncOGT and sOGT upregulation in proximal tubular cells. OGA-L, which is 
responsible for removing O-GlcNAc residues remained unchanged in all of the groups 
(Fig. 22C). Changes were not detected in mannitol-treated cells confirming that the 
observed phenomenon is a consequence of hyperglycemia and not of hyperosmolarity. 
 
  
Figure 22 Hyperglycemia-induced OGT elevation is prevented by DAPA treatment. (A-C) Protein levels of 
nucleocytoplasmic O-GlcNAc transferase (ncOGT), small O-GlcNAc transferase (sOGT) and O-GlcNAcase (OGA-L) 
of control, mannitol, high glucose (HG), dapagliflozin (HG+DAPA) and DAPA+losartan (HG+DAPA+LOS) treated 
high glucose HK-2 cells. Proteins were normalized to total protein Ponceau S staining as loading control. Bars indicate 
means±SDs and data were analyzed by one-way ANOVA with Holm-Sidak multiple comparisons test or Kruskal-
Wallis with Dunn comparison test (n=5-6/group). *p<0.05 vs. Control, **p<0.01 vs. Control, §p<0.05 vs. High glucose, 




4.7 High glucose-induced profibrotic growth factor increment is diminished by 
DAPA in proximal tubular cells 
 
We showed that diabetes-induced renal profibrotic growth factor increment was mitigated 
by DAPA; therefore, we investigated the effect of DAPA on TGFB1, PDFGB and CTGF 
in HK-2 proximal tubular cells cultured in hyperglycemic conditions. All growth factors 
were increased in HG conditions. DAPA significantly decreased the level of CTGF, while 
the level of TGFB1 and PDGFB remained unaltered. However, similarly to in vivo 
experiments a slight decrement was observed in PDGF. LOS treatment had no synergistic 
effect in vitro either (Fig. 23A-C).  
Figure 23 DAPA reduces hyperglycemia-induced CTGF expression in human proximal tubular cells (HK-2). (A-
C) mRNA expression of transforming growth factor β (TGFB1), platelet-derived growth factor (PDGFB) and 
connective tissue growth factor (CTGF) which were normalized to GAPDH mRNA expression. Bars indicate 
means±SDs and data were analyzed by one-way ANOVA with Holm-Sidak multiple comparisons test or Kruskal-




4.8 DAPA moderates tubular response to hypoxia 
 
4.8.1 Hypoxia-induced HIF-1α elevation is suspended by DAPA 
 
To investigate the effect of DAPA independently of its glucose-lowering action HK-2 
cells cultured in DMEM containing 25 mM glucose were placed into a hypoxic chamber 
(1% O2 for 2h). Hypoxic injury was investigated using three different methods (qRT-
PCR, Western blot, immunofluorescence analysis). In response to hypoxia, enhanced 
HIF-1α mRNA expression and protein level (by Western blot and immunocytochemistry 
as well) were observed. DAPA suspended HIF-1α elevation in both experiments 
indicating milder hypoxic injury. Moreover, DAPA treatment prevented HIF-1α 
translocation to the nucleus, thereby confirming abolished HIF-1α activation (Fig. 24A-





Figure 24 DAPA treatment minimizes tubular HIF-1α elevation. (A) HIF-1α mRNA expressions and (B) HIF-1α 
protein levels of control, hypoxia (H), dapagliflozin (H+DAPA) and DAPA+losartan (H+DAPA+LOS) treated hypoxic 
HK-2 cells. HIF1A was normalized to RN18S mRNA expression. Proteins were normalized to total protein Ponceau S 
staining as loading control. Proximal tubular cells were treated with DAPA or DAPA+LOS for 22 hours before 2 hours 
hypoxia (1% O2). Bars indicate means±SDs and data were analyzed by one-way ANOVA with Holm-Sidak multiple 
comparisons test or Kruskal-Wallis with Dunn comparison test (n=5-6/group).  **p<0.01 vs. Control, §p<0.05 vs. 





Figure 25 DAPA prevents HIF-1α translocation to the nucleus. (A) Hypoxia-inducible factor-1-alpha (HIF-1α) 
immunocytochemistry (green HIF-1α; blue nucleus; 20x objective; scale bar, 50 μm). (B) HIF-1α integrated density 
and (C) HIF-1α nucleus/cytosol ratio, protein levels of control, hypoxia (H), dapagliflozin (H+DAPA) and 
DAPA+losartan (H+DAPA+LOS) treated hypoxic HK-2 cells. Bars indicate means±SDs and data were analyzed by 
one-way ANOVA with Holm-Sidak multiple comparisons test or Kruskal-Wallis with Dunn comparison test (n=10 





4.8.1 Downstream elements of HIF pathway are moderated by DAPA 
 
Hematopoietic growth factor EPO is produced by the kidneys and regulates the 
production of red blood cells, thereby it is one of the key determinants of physiological 
oxygen homeostasis. VEGF, an angiogenic factor is produced by glomerular and tubular 
epithelia and it may help to restore vascular supply to cells, thereby reducing hypoxia 
(126). The HIF system is the central transcriptional mediator of these processes, therefore 
downstream elements EPO and VEGF-A were investigated. Both EPO and VEGF-A 
mRNA expressions and protein levels were enhanced in response to hypoxic insult and 
DAPA prevented the induction of EPO (Fig. 26A-D). 
 
Figure 26 DAPA moderates the downstream element EPO of HIF pathway.  (A) Erythropoietin (EPO) and (B) 
vascular endothelial growth factor A (VEGF-A) mRNA expressions of control, hypoxia (H), dapagliflozin (H+DAPA) 
and DAPA+losartan (H+DAPA+LOS) treated hypoxic HK-2 cells. EPO and VEGFA was normalized to RN18S mRNA 
expression. (C) EPO and (D) VEGF-A protein levels. Proteins were normalized to total protein Ponceau S staining as 
loading control. Bars indicate means±SDs and data were analyzed by one-way ANOVA with Holm-Sidak multiple 




4.8.2 DAPA alters profibrotic growth factor expression in response to hypoxia 
 
Hypoxia triggers fibrotic response, thus TGF-β, PDGF and CTGF were investigated. 
TGFB1, PDGFB and CTGF mRNA expressions increased in hypoxic tubular cells. 





Figure 27 Hypoxia-induced profibrotic growth factor mRNA expressions were diminished by DAPA. (A) 
Transforming growth factor beta 1 (TGFF1), (B) platelet derived growth factor subunit B (PDGFB) and (C) connective 
tissue growth factor (CTGF) of control, hypoxia (H), dapagliflozin (H+DAPA) and DAPA+losartan (H+DAPA+LOS) 
treated hypoxic HK-2 cells. TGFB1, PDGFB and CTGF was normalized to RN18S mRNA expression. Bars indicate 
means±SDs and data were analyzed by one-way ANOVA with Holm-Sidak multiple comparisons test (n=5-6/group).  






Diabetes is a serious global health issue that has reached alarming levels; today, nearly 
half billion adults are living with diabetes worldwide. If current trends continue, ~700 
million people are predicted to have diabetes by 2045 (3). DKD, a microvascular 
complication develops in approximately 30-40% of diabetic patients and is the leading 
cause of ESRD. The escalating prevalence of DKD parallels the dramatic worldwide rise 
of diabetes; therefore, novel therapies and early intervention directly targeting the diabetic 
kidney are of paramount importance.  
 
The management of DKD mainly aims to regulate metabolic and hemodynamic 
abnormalities.  Current guidelines recommend ACEi or ARBs as the first-line therapy for 
hypertensive patients with diabetes, especially when renal involvement is present. ACEi 
and ARBs improve renal outcomes in patients with CKD causing improved blood 
pressure control and decreased proteinuria. Aldosterone antagonists are still mainly used 
as diuretics in the treatment of hypertension. Increased aldosterone levels were reported 
in CKD patients treated with ACEi or ARBs, called the “aldosterone escape 
phenomenon” (127, 128). This supports the use of aldosterone antagonists in addition to 
ACEi or ARBs, which further reduces albuminuria in DKD; however, at the risk of 
worsening hyperkalemia.  
 
Impaired renal function and pathophysiological changes including glomerulosclerosis, 
progressive mesangial expansion, tubulointerstitial fibrosis and endothelial injury are the 
result of hypertension, hyperglycemia, activated RAAS and various other factors. 
Furthermore, aldosterone alone also promotes proteinuria and renal fibrosis (129). 
Therefore, identification of therapeutics controlling the pathological fibrogenic response 
would be beneficial for DKD treatment. Thus, the aim of our first experiment was to 
evaluate the monotherapeutic effect of different RAASi in diabetes-induced renal 
fibrosis. The antifibrotic potential of different RAASi has already been shown in various 
animal models (130-132). To test whether the antifibrotic properties of RAASi are 




doses avoiding blood pressure changes. In this study, neither diabetes nor RAASi affected 
blood pressure confirming the non-depressor doses used in our protocol. 
 
In line with our previous studies, loss of renal function and severe structural damage were 
observed in diabetic rats (119). All RAASi improved classic retention parameters. 
According to our results, RAASi in monotherapy are effective in ameliorating diabetes-
induced tubulointerstitial fibrosis. From the first part of our experiments one can conclude 
that in this T1DM rat model RAASi successfully minimize renal functional decline and 
reduce fibrosis independently of their antihypertensive properties. These results might 
support the indication of RAASi as renoprotective agents, but human clinical trials are 
needed to confirm this suggestion and to evaluate of the risk/benefit ratio, especially of 
aldosterone antagonists. Futhermore one can hypothesize that antifibrotic effect of 
RAASi might be used as therapeutic option in kidney fibrosis originated from other 
diseases. 
 
Glycemic control and RAAS inhibition have long been the mainstream therapy in patients 
with DKD. RAAS inhibition with ACEi and ARBs reduces albuminuria, but cannot fully 
prevent renal failure. Beyond these recommendations, clinicians have little else to offer 
DKD patients; hence, there is a great demand for novel therapies. 
 
SGLT2i are the newest breakthrough antidiabetics showing potent renoprotective effect 
recently proven in large clinical multicenter trials. From the EMPA-REG OUTCOME 
trial (112) to the CANVAS Program (133) and later to the DECLARE-TIMI 58 trial (134) 
SGLT2i have shown a significant and reproducible attenuation of the rate of GFR decline 
and a reduction in the risk of progression to ESRD. These findings were confirmed in the 
CREDENCE trial which is the only study reported so far designed specifically to assess 
the effects of canagliflozin on renal outcomes (114). The renoprotective effects of 
SGLT2i were consistent across studies indicating that renoprotection seems to be a class 
effect of SGLT2i. However, this observation has not been confirmed in T1DM yet and 
the molecular background is not fully understood. Therefore, the primary goal of our 
second experiment was to investigate the renoprotective effect of DAPA in a STZ-




synergistic effect of DAPA combined with ARB LOS. DKD is traditionally presumed to 
predominantly affect the glomeruli, but proximal tubules play a role as an initiator and 
contributor in the early pathogenesis of DKD (135). The focus of our study was on the 
proximal tubule, where chronic hyperglycemia elevates tubular glucose load, increased 
exposure and reabsorption lead to structural and functional changes. 
 
Decline in renal function and severe structural damage were observed in diabetic rats 
similarly to our previous experiments confirming the reproducibility of the STZ-model. 
Here we showed that DAPA treatment prevented the progression of renal functional and 
structural damage. Beside the classic renal retention parameters, early and highly 
sensitive biomarkers of renal tubular damage were investigated (124, 125). KIM-1 and 
NGAL are expressed at very low levels in the normal human and rodent tubules, but they 
are upregulated in response to structural renal injury. Urinary elevation of KIM-1 and 
NGAL in T1DM patients was demonstrated in a cross-sectional study indicating tubular 
damage at an early stage (136). A recent study showed that renal KIM-1 and NGAL were 
decreased in DAPA-treated T2DM rats (137). In our T1DM model, DAPA reduced both 
urinary and renal KIM-1 and NGAL by 50% proving milder tubular damage. The 
preventive effect of DAPA was substantiated by a robust improvement of all retention 
parameters and novel biomarkers. 
 
Renal fibrosis is the common final pathway of nearly all chronic and progressive 
nephropathies. Chronic injury such as diabetes leads to fibrotic matrix deposition 
disrupting kidney architecture, reducing blood supply and ultimately disturbing renal 
function. In the diabetic milieu, connective tissue accumulation leads to tubulointerstitial 
fibrosis which is characterized by dysregulation of ECM remodeling and matrix protein 
deposition secreted by activated myofibroblasts (138). TGF-β is the primary driver of 
fibrosis resulting in myofibroblast activation, excessive ECM production and inhibition 
of ECM degradation (139). PDGF and CTGF also play a key role of EMT and ECM 
production (140, 141). A more recent study showed that DAPA attenuated renal 
tubulointerstitial fibrosis in a mouse model of T1DM (142). Recently in a DKD network 
model combined with plasma measurements of fourty-four T2DM patients Heerspink et 




induced ECM turnover and fibrosis (143). We demonstrated that DAPA successfully 
regulates the diabetes-induced fibrotic response and suppresses the level of profibrotic 
growth factors Ctgf and Pdgfb. Concurrently myofibroblast marker α-SMA and 
accumulation of ECM components, collagens and fibronectin were less increased in 
DAPA-treated diabetic kidneys as well. Here we provide novel data of the antifibrotic 
properties of DAPA strengthening the previous experimental and clinical observations. 
 
At the moment kidney biopsy is the diagnostic method of renal fibrosis, which is an 
invasive process with possible complications (144); therefore, research is ongoing to 
discover specific non-invasive urinary or serum markers. Formation and degradation of 
ECM components leads to specific Protein FingerprintTM peptides: fragments derived 
from the collagen pro-peptides describe active collagen formation, while neo-epitope 
fragments of collagen mediated by MMP cleavage reflect collagen degradation. These 
peptides coming from the remodeling kidney are released into urine and can be measured 
by newly developed immunoassays (145). We showed in two different studies that the 
level of Protein FingerprintTM peptides, rPRO-C3 (collagen type III formation), uC3M 
(collagen type III degradation) and TUM (collagen type IV degradation) were increased 
in the urine of T1DM rats (146). Moreover, DAPA mitigated the increased levels of 
rPRO-C3 and TUM reverting them to the level of controls. Our findings and the positive 
correlation between these urinary markers and tubulointerstitial fibrosis further prove the 
antifibrotic property of SGLT2i. We hope our results encourage the validation and 
widespread clinical use of these novel non-invasive biomarkers of ECM remodeling. 
 
Since RAASi and SGLT2i have different mechanism of action, it is reasonable to apply 
combination therapy, however to our best knowledge it has not been previously tested in 
T1DM at all and data in other diseases are also limited. Studies suggest that STZ-induced 
T1DM is more relevant for investigating DKD, because glucotoxicity could be examined 
without the frequent comorbidities of T2DM such as insulin resistance, obesity, vascular 
disease, hypertonia or ageing. Rather surprisingly, in our experiments DAPA alone was 
as effective as the combination therapy with LOS both concerning in vivo and in vitro 





There are some results in clinical as well as experimental T2DM setups, but in each case 
combination therapy was used when hypertension was present. Combination of DAPA 
with RAASi resulted in lower albuminuria in T2DM patients, however studies were not 
designed to assess whether the effect of DAPA on renal variables was independent of 
glucose or blood pressure control, neither proved the synergistic effect of these two versus 
other comparators (116). In another study in patients with uncontrolled hypertension by 
RAASi the value of additional DAPA treatment was assessed on the improvement of 
blood pressure. This study proved that DAPA reduces blood pressure and body weight in 
T2DM patients with hypertension and diminishes the need for additional antihypertensive 
therapy (147).  Interestingly enough addition of DAPA resulted in a negative result, since 
no further albuminuria-lowering effect was detected. In a T2DM rat model 12 weeks of 
combination therapy of DAPA and irbesartan offered more improvement in renal 
retention and histological parameters and renal fibrosis than use of either agent separately 
(148). In Dahl salt-sensitive hypertensive STZ rats combination therapy of luseogliflozin 
with ACEi afforded greater reduction of blood pressure, hyperfiltration and structural 
injury. Of note gliflozin therapy did not have any effect on proteinuria, which argues the 
renoprotective efficacy of the treatment (149). Lastly, variances in experimental setups 
and protocols could explain the divergences in outcomes and more data and extended 
investigations are needed to clarify the possible benefits of combination therapy. 
 
The most recent multinational observational cohort study showed that SGLT2 inhibition 
was associated with a slower rate of kidney function decline and lower risk of clinically 
meaningful kidney events compared with use of other glucose-lowering drugs in real-
world clinical practice databases of T2DM patients (150). One possible explanation for 
the protective effect of SGLT2i is the induction of multiple processes that have a 
synergistic beneficial influence on renal and cardiovascular systems e.g. reduction in 
glucotoxicity, blood pressure and hyperfiltration. The “tubular hypothesis” is based on 
the fact that hyperglycemia causes increased tubular glucose load leading to SGLT 
overactivation and consequent enhanced tubular reabsorption of glucose and sodium and 
downstream activation of TGF. SGLT2i restore TGF resulting in normal GFR (151). 




improve hard renal end points. However, there is not sufficient knowledge to prove that 
the renal end points are the result of the associated hemodynamic effects (152).  
 
Various hypotheses exist in the literature regarding how SGLT2i improve renal function 
and reduce kidney injury in T2DM rodent models. Recent papers discuss that SGLT2i 
ameliorate DKD via improving glycemic control along with inhibiting inflammation and 
oxidative stress (153-155). Hyperglycemia-induced renal injury is a complex 
phenomenon in itself involving various processes in proximal tubules among which 
increased activation of alternative glucose metabolism pathways and hypoxia have a 
strong impact and were the focus of our in vitro investigations. 
 
O-GlcNAcylation has been shown to have a major role in the regulation of renal 
transcription factors. Dysfunction of transcription factor Sp1 results from O-GlcNAc 
modifications in diabetes. O-GlcNAcylation plays an essential role in high glucose-
induced Sp1 transcriptional activity and upregulation of PAI-1 and TGF-β expression 
contributing to the development of renal fibrosis (67-69). Increased O-GlcNAcylation has 
been reported to enhance fibrogenesis in mesangial cells exposed to high glucose (156, 
70). We previously showed that protein O-GlcNAcylation (157) and fibrotic processes 
were induced (146) in diabetic rats as well as in hyperglycemic HK-2 cells. Since DAPA 
blocks glucose uptake in proximal tubular cells (158) we hypothesized that it can modify 
protein O-GlcNAcylation thus affecting fibrotic processes. DAPA minimized the 
enhanced protein O-GlcNAcylation and reduced OGT levels in HK-2 cells. However, 
OGA, which is responsible for removing O-GlcNAc residues, remained unchanged 
suggesting that DAPA may inhibit the addition of O-GlcNAc rather than facilitate its 
removal.  
 
When proximal tubular cells are exposed to high glucose due to elevated glucose 
trafficking through SGLT2, the expression of profibrotic factors is increased, which 
promotes fibrosis (159). A recent study showed that empagliflozin reduces glucose-
induced fibrotic markers in HK-2 cells (160). Therefore, we measured profibrotic growth 
factors, which were all upregulated in hyperglycemic conditions. Here we found that 




elevated after DAPA treatment confirming milder injury. Surprisingly TGFB1 and 
PDGFB were not affected. The antifibrotic effect of DAPA is maybe a consequence of 
O-GlcNAcylation decrement. According to our in vivo and in vitro results it is tempting 
to hypothesize that SGLT2i might be particularly useful in ameliorating tubulointerstitial 
fibrosis in diabetic patients with tubulointerstitial lesions. 
 
In light of these data it is difficult to understand whether these beneficial effects are 
simply related to the reduction of blood glucose or to synergistic direct protective renal 
effects. Hence, to investigate whether DAPA is renoprotective independently of its 
antihyperglycemic effect, an in vitro low-grade hypoxia model was applied in HK-2 cells. 
Recently, tubular hypoxia and altered O2 handling have received increased attention for 
their putative roles in the development and progression of DKD (161). Various models 
and methods throughout the years have confirmed decreased renal tissue O2 tension in 
diabetic rats (76, 77). Glomerular hyperfiltration and elevated glucose reabsorption 
through SGLTs enhances Na+/K+-ATPase activity resulting in increased O2 consumption 
in hyperglycemia (162). In response to low O2 levels cells activate adapting mechanisms 
which are primarily controlled by the master regulator HIF system (163, 78). During 
hypoxia HIF-α stabilizes and translocates from the cytoplasm to the nucleus, where it 
dimerizes with HIF-β and the HIF complex binds to hypoxia responsive elements in the 
promoter sequences of numerous genes involved in cellular O2 homeostasis (164).  
 
Our experimental setup (1% O2, 5% CO2 and 94% N2) is a widely accepted model of 
hypoxia (165). As a general hypoxic response Wang et al. demonstrated that HIF-1α is 
activated under 1% O2 concentration in a large variety of cell types (e.g. mouse Ltk
- 
fibroblasts, Chinese hamster ovary cells, rat fibroblasts, human Hep3B hepatoblastoma 
cells or HEK cells) (166). HIF-1α has also been reported to be elevated in 1% O2 milieu 
specifically in proximal tubular cells (167-169). Therefore, we used the hypoxic chamber 
model in which massive HIF-1α elevation was verified by three different methods (qRT-
PCR, Western blot, immunocytochemistry). All these data confirmed the severe hypoxic 
insult and the relevance of HIF-1α as a hypoxia marker. In parallel, nuclear translocation 
of HIF-1α was investigated. DAPA suspended hypoxia-induced HIF-1α elevation and 




To confirm this phenomenon downstream elements of the general HIF pathway were 
investigated. After dimerization, the HIF complex binds to hypoxia responsive elements 
in the promoter sequences of numerous genes involved in maintaining cellular and tissue 
O2 homeostasis. EPO is mainly produced by renal fibroblasts; however, tubular epithelial 
cells, glomerular mesangial cells and interstitial fibroblasts can produce it as well (170). 
HIF-1α and HIF-2α share many transcriptional targets, EPO appears to be co-regulated, 
while VEGFA is regulated by HIF-1α. Therefore, we measured the mRNA and protein 
levels of EPO and VEGFA, which were all induced in response to hypoxia. Parallel to 
HIF-1α EPO was less elevated in DAPA-treated cells, while VEGFA was not affected. 
In conclusion, DAPA directly moderates the tubular response to hypoxia as shown by 
reduced HIF-1α and EPO production. Based on our results one can hypothesize that 
SGLT2i might be useful in preventing hypoxic injury in kidney diseases of various 
origins. 
 
Recently, chronic tubulointerstitial hypoxia has been postulated as a final common 
pathway to ESRD. Chronic hypoxia and subsequent increased HIF expression may be 
profibrotic and HIF activation may itself induce fibrosis. Hypoxia triggers transformation 
of tubular cells into myofibroblasts (171). In response to low O2 tension matrix protein 
production is upregulated and matrix degradation is suppressed in tubular cells leading to 
ECM accumulation (82). Hypoxia also induces TGF-β expression, moreover the two can 
act synergistically in VEGF and EPO regulation (83, 84). HIF activation plays an 
important role in the direct transcriptional regulation of profibrotic growth factors (85, 
172). Thus, we investigated TGFB1, PDGFB and CTGF mRNA expressions in hypoxic 
tubular cells, which were all upregulated. Here we showed that DAPA decreased hypoxia-
induced TGFB1 and PDGFB production suggesting that its antifibrotic effects might be 
in direct connection with diminished hypoxia. A detailed clarification of the effect of 
SGLT2i on hypoxia-induced HIF-mediated complex molecular pathways was beyond the 
main scope of this study; however, our observations might open a new potential for 






Our results are the first experimental evidence for the antifibrotic properties of non-
depressor dose of RAASi offering a possible novel indication for them in the treatment 
of kidney fibrosis. Our findings have outlined the robust preventive and protective effect 
of DAPA in experimental T1DM providing a novel therapeutic option to minimize DKD. 
The antifibrotic effect of DAPA was proved under hyperglycemic and hypoxic conditions 
that occur simultaneously in the diabetic kidney. These findings provide fresh data 
supporting the link between glucose toxicity, tubular hypoxia and fibrosis, a vicious trio, 
which seem to be targeted by DAPA. All these mechanisms are important parts in the 
puzzle of the complex system behind the organoprotective effect of SGLT2i. Ultimately, 
our results might support the latest findings that treatment with SGLT2i could be 










1. Treatment with non-depressor doses of RAASi in monotherapy is renoprotective and 
antifibrotic in a rat model of T1DM. 
 
2. SGLT2 inhibitor DAPA treatment is protective in T1DM and subsequent DKD. It 
substantially ameliorates functional and structural kidney damage. 
 
3. Our in vivo and in vitro experiments revealed that DAPA has antifibrotic properties. It 
mitigates the level of novel urinary biomarkers of ECM remodeling, profibrotic growth 
factors and accumulation of collagen and fibronectin. 
 
4. Hyperglycemia-induced protein O-GlcNAcylation in proximal tubules is minimized by 
DAPA. 
 
5. DAPA directly moderates the tubular response to hypoxia independently of its 
antihyperglycemic property. 
 
6. DAPA alone is as effective as the combination therapy with non-depressor LOS both 






Diabetes and subsequent complication diabetic kidney disease (DKD) lead to a global 
health crisis and effective therapies are lacking. Current guidelines recommend 
angiotensin-aldosterone system (RAASi) as the main therapy; however, these merely 
ameliorate renal impairment, but cannot prevent renal failure. Thus, novel therapies and 
early intervention directly targeting the diabetic kidney are of paramount importance. 
 
Proximal tubular sodium-glucose cotransporter 2 inhibitors (SGLT2i) are the newest 
breakthrough antidiabetics. Multicenter clinical trials proved that SGLT2i considerably 
hinder the progression of DKD. However, this observation has not been confirmed in 
T1DM yet and the molecular background is not fully understood. 
 
Proximal tubules play a significant role in the early pathogenesis of DKD. Renal fibrosis 
is the final common pathway of chronic nephropathies. Increased protein O-
GlcNAcylation enhances profibrotic signaling during hyperglycemia. Elevated tubular O2 
demand leads to hypoxia, which is also a major contributor of fibrogenesis. During my 
PhD work we aimed to investigate the preventive and antifibrotic effects of RAASi and 
DAPA in DKD with special focus on protein O-GlcNAcylation and tubular hypoxia. 
 
We showed that treatment with non-depressor dose of various RAASi is renoprotective 
and antifibrotic in a rat model of T1DM offering a possible novel indication in the 
treatment of kidney damage. Moreover, we demonstrated that DAPA is preventive and 
protective in experimental T1DM; it ameliorates functional and structural kidney damage. 
Our in vivo and in vitro experiments revealed that DAPA has antifibrotic properties in 
hyperglycemia and hypoxia partly via minimizing O-GlcNAcylation and moderating the 
tubular response to hypoxia. Our results support the link between glucose toxicity, tubular 
hypoxia and fibrosis, a vicious trio that may be targeted by DAPA.  
 
Ultimately, our results may support the latest findings that treatment with SGLT2i could 








A diabétesz szövődményeként kialakuló diabéteszes vesebetegség (DKD) globális 
népegészségügyi probléma, amely hatalmas terápiás kihívás. Jelenleg a renin-
angiotenzin-aldoszteron rendszer (RAAS) gátlók a gold standard kezelés DKD esetén, 
melyek javítják a vesefunkciót, de a betegség progresszióját nem állítják meg, ezért új 
terápiás megoldásokra van szükség. 
 
A legújabb antidiabetikum csoport, a vese proximális tubulusaiban ható Na+-glükóz 
kotranszporter 2 gátlók (SGLT2i) áttörést hoztak a diabétesz terápiájában. Klinikai 
vizsgálatokban kimutatták, hogy az SGLT2i a vércukorszint csökkentése mellett 
jelentősen gátolják a DKD előrehaladását, azonban a pontos molekuláris mechanizmusok 
nem egyértelműek. 
 
A proximális tubulus kiemelt szerepet játszik a DKD korai patogenezisében, mely végső 
soron fibrózishoz vezet. A hiperglikémia következtében megnövekedett fehérje O-
GlcNAciláció indukálja a profibrotikus útvonalakat. A megnövekedett tubuláris oxigén 
igény hipoxiához vezet, amely szintén hozzájárul a fibrózishoz. PhD munkám célja a 
különböző RAAS gátlók és DAPA preventív és antifibrotikus hatásainak vizsgálata, 
különös tekintettel a fehérje O-GlcNAcilációra és a tubuláris hipoxiára. 
 
T1DM patkánymodellben kimutattuk, hogy a különböző RAAS gátlók non-depresszor 
dózisban renoprotektívek és antifibrotikus hatásúak, mely hozzájárulhat egy új lehetséges 
indikáció bevezetéséhez vesekárosodás esetén. Bizonyítottuk, hogy a DAPA preventív és 
protektív hatású, javítja a vesefunkciót és mérsékli a struktúrális károsodást. A DAPA 
csökkenti a tubuláris O-GlcNAcilációt és vércukor csökkentő hatásától függetlenül 
mérsékli a hipoxiás károsodást tubulus sejtekben, ezáltal hozzájárulhat a fibrózis 
kivédéséhez. 
 
Eredményeink alátámaszthatják a legújabb megállapításokat, miszerint az SGLT2i 
kezelést a legtöbb, ha nem az összes T2DM betegnél fontolóra lehet venni a DKD 
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Figure 1 Estimated total number of diabetic adults (20-79 years) in 2019. 
Figure 2 Stages of diabetic kidney disease. 
Figure 3 Protein O‑GlcNAcylation is regulated by the nutrient flux via the hexosamine 
biosynthetic pathway. 
Figure 4 Oxygen regulates HIF-α protein expression. 
Figure 5 Renal glucose reabsorption is mediated by SGLT2 and SGLT1. 
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Figure 11 Diabetes-induced SGLT2 and GLUT2 increment is mitigated by DAPA. 
Figure 12 DAPA treatment slows the decline of renal function. 
Figure 13 Early and sensitive biomarkers of tubular damage is decreased by DAPA. 
Figure 14 Mesangial matrix expansion was ameliorated in the diabetic kidney by 
DAPA. 
Figure 15 Novel urinary biomarkers of ECM remodeling are decreased in the DAPA-
treated diabetic rats. 
Figure 16 Profibrotic growth factor mRNA expressions were diminished by DAPA. 
Figure 17 DAPA reduces tubulointerstitial fibrosis. 
Figure 18 Tubulointerstitial fibrosis correlates with urinary markers of ECM 
remodeling. 
Figure 19 Diabetes-induced collagen deposition are ameliorated by DAPA. 
Figure 20 DAPA reduces fibronectin deposition and mRNA expression. 
Figure 21 DAPA reduces hyperglycemia-induced protein O-GlcNAcylation in human 
proximal tubular cells. 




Figure 23 DAPA reduces hyperglycemia-induced CTGF expression in human proximal 
tubular cells. 
Figure 24 DAPA treatment minimizes tubular HIF-1α elevation. 
Figure 25 DAPA prevents HIF-1α translocation to the nucleus. 
Figure 26 DAPA moderates the downstream element EPO of HIF pathway. 
Figure 27 Hypoxia-induced profibrotic growth factor mRNA expressions were 
diminished by DAPA. 
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